University of Rhode Island

DigitalCommons@URI
Open Access Master's Theses
2001

COMPARING SEVERAL SELF-REPORT MEASURES OF
ADHERENCE WITH MEDICATIONS FOR HIV WITH
ELECTRONICALLY MONITORED MEDICATION ADHERENCE.
Neelam Awte
University of Rhode Island

Follow this and additional works at: https://digitalcommons.uri.edu/theses

Recommended Citation
Awte, Neelam, "COMPARING SEVERAL SELF-REPORT MEASURES OF ADHERENCE WITH MEDICATIONS
FOR HIV WITH ELECTRONICALLY MONITORED MEDICATION ADHERENCE." (2001). Open Access Master's
Theses. Paper 234.
https://digitalcommons.uri.edu/theses/234

This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information,
please contact digitalcommons@etal.uri.edu.

(
COMP ARING SEVERAL SELF-REPORT MEASURES OF ADHERENCE WITH
MEDICATIONS FOR HIV WITH ELECTRONICALLY MONITORED
MEDICATION ADHERENCE.

BY
NEELAMAWTE

A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE
f

REQUIREMENTS FOR THE DEGREE OF
MASTER OF SCIENCE
IN

PHARMACY ADMINISTRATION

UNIVERSITY OF RHODE ISLAND

(

2001

MASTER OF SCIENCE THESIS
OF
NEELAMAWTE

APPROVED:
Thesis Committee

(

OF THE GRADUATE SCHOOL

UNIVERSITY OF RHODE ISLAND
2001

(
ABSTRACT
Objective: Self-report of medication adherence is commonly used in research studies,
but the information is lacking about the sensitivity, specificity, reliability and clinical
validity of this method. The purpose of this study was to test the sensitivity, specificity
and reliability of several methods for accessing medication compliance using patient
self-report of adherence. The Medication Event Monitoring System (MEMS) was used
as a standard against which self-report measures were compared.

Design: Cross sectional study.
Data Collection: A self-reported questionnaire accessed compliance of Anti-retroviral
therapy (ART) and Protease inhibitors (PI) used by the patients with IIlV infection
during the year 1996-1997. The eligibility criteria included ages between 18-74 years,
a current prescription of ART or PL One hundred and forty- five patients completed
the questionnaire out of which a subset of 86 patients were randomly selected to
receive a 30-day supply of their prescribed anti-retroviral in a vial with MEMS Track
cap. After a period of one month the data was retrieved using MEMS-4 communicator.
Data on demographics, mood status, medical status and clinical characteristics was
also obtained by survey.

Methodology: Sensitivity, specificity and reliability were calculated for the following
self-report measures: number of doses missed in past one month, number of doses
missed in past three months, Medication Adherence Scale (MAS) and temptation to
skip medication scale. The patient population was divided into two groups, i.e., the
patients on PI and patients on ART. MEMS report was used as a standard for

11

comparison of the self-reported compliance. Two different gold standards were set.
>80% compliance MEMS and >90% compliance MEMS to test the compliance at
80% and 90% cutoffs.
Results: For patients on Protease inhibitors, the agreement between Self-report and
MEMS-report according to kappa statistics was K= 0.14 (for >80% compliance
MEMS) and K=0.11 (for >90% compliance MEMS) indicating only slight agreement
between the two measures of compliance. Number of doses missed in past one month
and number of doses missed in the past three months had the highest sensitivity of
1.00, but the specificity of these measures was very poor. MAS had the highest values
of kappa (K=0.26) indicating a fair amount of agreement with MEMS. Temptation to
skip medication scale showed a good balance of sensitivity and specificity, indicating
good accuracy. For patients on ART the agreement between the Self-report and
MEMS-report according to the kappa statistics was K=0.15 (for >80% compliance
MEMS) and K=0.20 (for >90% compliance MEMS) indicating only slight agreement
between the two measures of compliance. In congruence with the results for PI
patients, number of dose missed in past one month and number of doses missed in past
three months overestimated adherence. MAS had the highest kappa value of K=0.33
indicating fair agreement with MEMS and temptation to skip medication showed a
good balance between sensitivity and specificity, similar to PI patients.
Conclusion: Sensitivity and specificity are the measures of accuracy of the data.
Number of doses missed in past one month and number of doses missed in the past
three months showed highest sensitivity, indicating that this measure correctly
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classified the complaint patients in the complaint category. At the same time these
measures had a very low specificity indicating that the non-compliant patients were
also incorrectly classified as compliant, causing overestimation of compliance
behavior, leading to erroneous results. MAS and temptation to skip medication
measures also overestimated adherence, concluding a very low accuracy of these
measures in detecting compliance. Kappa statistics is an index of reliability. All the
self-report measures only showed a slight to fair agreement with MEMS reported
compliance indicating a very low reliability of these self-report measures in measuring
compliance. Additional studies will be required to determine if these findings also
apply to other populations.
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INTRODUCTION
Adherence, often used interchangeably with compliance, is "the act, action, or quality
of being consistent" [1] with administration of prescribed medications. Adherence is
preferred because it affirms that a patient actively participates in choosing and
maintaining a medication regimen. Nonadherence may mean not talcing medication at
all, taking reduced amounts, not talcing doses at prescribed frequencies or intervals or
not matching medication to food requirements [2]. Typical rates of medication
adherence for persons with chronic disease are about 50%, with a range from 0% to
100% [3].

A] Importance of Adherence
As protease inhibitors and triple drug combinations have become the standard of care
for most HIV patients, adherence to HIV medication regimens has become an
important issue [4] . Since HIV has the ability to mutate rapidly in absence of drug or
at sub- therapeutic doses, taking anti-retroviral medication exactly as prescribed is the
required the success of antiretroviral therapy [5,2].
Adherence to anti-retroviral therapy for the treatment of HIV infection and AIDS has
become one of the most important clinical challenges among HIV health care
providers and patients [4,6]. One hundred percent adherence to current anti-retroviral
regimen however is not easy to achieve. Research on adherence of HIV therapy ranges
from 46% to 88% [7-10] . It has also been shown that adherence normally decreases
over time and with greater number of pills that one is required to take.
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Improvement of adherence is key to preventing the emergence of drug-resistant
viruses that compromise therapeutic benefits and may be transmitted to others.
Furthermore, the cost of interventions to enhance adherence is minimal as compared to
the cost of the therapy [2].

B] Measuring Adherence:
The measurement of adherence poses a challenge to researchers and clinicians. There
are a number of ways to measure adherence or compliance [ 11, 16].
Current detection methods include indirect measures, such as self-report, interviews,
therapeutic outcomes, pill count, change in the weight of meter-dose inhaler canisters,
( .

medication refill rate and computerized compliance monitors, and direct measures,
such as biologic markers, tracer compounds, and biologic assay of body fluids [12].
Plasma and urinary drug levels provide useful objective assessment of adherence but
are often subject to wide individual variation in drug pharmacokinetics [13]. Drug
levels may only reflect doses taken the previous day rather than adherence over the
previous week or month [14]. This problem is particularly true for medications with
short half-lives. In addition, most drug assays are expensive and subject to multiple
confounding sample methods [14,15].
Pill count is another common detection method used to measure compliance. It is
frequently used in clinical drug studies, but the results can be confounded if unused
bottles are misplaced or deliberately not returned to the providers also called "pill-
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dumping" [16]. In addition, pill counts do not reveal whether a medication is taken
consistently or at correct dosing intervals.
Refill records at pharmacies capture the quantity of medication presumably consumed
between visits but cannot verify correct timing of doses or the actual taking of
medication [17].
Self-report and interviews with patients are the most common and simplest methods
of attempting to determine compliance with the therapy [12]. It is the only method
that can detect the underlying issues related to non-adherence behavior, and it is
therefore critical to incorporate some type of self-report in evaluating an adherence
strategy [18].
This method has an advantage of low cost, results are easily obtainable and the
method can be tailored to the language and reading competency of the subjects.
Disadvantages of this method include: overestimation of adherence, recall bias and
the fact that this method often gives information only on short-term adherence or
average adherence. One of the ways suggested to improve self-reporting methods is
to include computer-assisted interviews, which may give more accurate results
especially on sensitive questions [19].
The method in which 'self-report' is administered is an important aspect of getting
useful information from patients. The way in which the questions are asked also
plays a role in the quality of information received. Phrasing the question in a nonjudgmental way and asking for specific information has been found to be critical in
obtaining important information on how the patient is managing with adherence.
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Some examples of this are: "It is sometimes difficult to take these medications
exactly on time. How many doses have you missed in the past 24 hours?" and "Do
you miss some of your medications each week?" [18).
One study found that phrasing question to elicit a "yes" response to non-adherence
behavior allowed patient to disclose actual behavior more readily because the patients
have the tendency to answer providers in the affirmative [20). This supports the
notion that providers will get more accurate information if they give their patients
permission to be honest about their difficultly in taking medication.
An ideal method for measuring compliance should measure compliance at the time
and place of medication-taking event. It should, therefore, possess perfect sensitivity
and specificity. Although direct observation of the patient would come closest to
satisfying the definition, this method is not practical.
Computerized compliance monitors are the most recent and reliable source of indirect
detection methods. Hence they were used in this study as a gold standard to compare
self-report measures. The principle of electronic monitoring of compliance was
pioneered by Kass et al., [21,22] with the development of an electronic eye-drop
dispenser. Electronic monitoring also has been used to measure compliance with
solid dosage forms (Medication Event Monitoring Systems [MEMS] available from
Aprex Corporation, Fremont, Califomia.)[21,22). This technique uses a computer
chip in the cap to record the time when the medication bottle is opened and
presumably a pill is taken. This method has the disadvantages of underestimating the
adherence if multiple doses are removed at one time or estimating adherence if the
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medication is not actually taken, it is expensive and it also requires specific software
for interpretation.

C] Measurement Error
A certain amount of error is intrinsic to any measurement process. In the conduct of
epidemiologic research, measurement error is potentially a major problem that may
invalidate the results of otherwise well-designed studies. Although measurement error
can never be eliminated, the methods for minimizing the impact can contribute greatly
to the quality of epidemiologic studies and to the appropriateness of the conclusions
drawn from them.

Indices of accuracy of measurement:
The accuracy, or validity, of a measurement refers to the extent to which the
measurement represents the true value of the attribute being assessed. In order to
obtain something more than an impressionistic idea of the quality of a measurement of
a given variable, it is useful to calculate quantitative indices of the accuracy of
measurement. For a discrete variable there are two separate aspects of the accuracy of
measurement. One is sensitivity, which is defined as the proportion of those who truly
have the characteristic that are correctly classified as having it by the measurement
technique [23]. The other is specificity, which is defined as the proportion of those
who truly do not have the characteristic that are correctly classified as not having it by
the measurement technique [23]. Measurement of a binary characteristic is perfect
when both sensitivity and specificity are 100%. When sensitivity is equal to 100%
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minus specificity, then the measurement technique is no better than an entirely random
mean of classifying individuals, which indicated that the probability of being
identified as having characteristic is same for those who do not have the characteristic.
In order for a measurement technique to be useful in epiderniologic research, it must
be substantially better than a random method of classification.

Indices of reliability:
In many epidemiologic studies, it is important to assess the degree of correspondence
of two qualitatively differently methods of measurement, such as information on use
of medications obtained through interviews compared with similar information
obtained through review records. The extent of their agreement in classifying the
individuals would then reflect the reliability of the measure used.
The kappa coefficient is appropriate for comparing agreement between discrete
variables. The kappa coefficient, which was first proposed by Cohen (1960), has the
important characteristic of correcting for the chance agreement that would be expected
to occur if the two classifications were completely unrelated. Failure to take into
account chance agreement can lead to erroneous conclusions about the quality of
measurement.
The relationship of kappa to sensitivity and specificity under the assumption of
independent error is more complex and is a function not only of these two indices of
accuracy, but also of the true proportion of the population that in fact has the
characteristic of interest (compliant) [24,25]. Consequently, even for fixed values of
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sensitivity and specificity, the value of kappa can vary widely, so that inferences about
accuracy based on the value of kappa are difficult to draw.
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METHODOLOGY
Study Sample
The sample consisted of 145 patients who were currently prescribed medication for
IDV. Eligibility criteria included age between 18 and 74 years, a current prescription
of approved anti-retroviral medication or protease inhibitors or use of approved
medication for IDV-related complications and prophylaxis of opportunistic infections
(for

example,

trimethoprim,

sulfamethoxazole

used

in

the

prophylaxis

of

Pneumocystic carinii pneumonia), ability to read English, and positive IDV status. The
purpose of the original study for which the data was gathered was to develop measures
of stages of change for medication adherence. The study was funded by NIH and
conducted by Dr. Cynthia Willey, at the University of Rhode Island during the year
1995-1998.
The study sites are described below:
1. The Miriam Hospital Immunology Center, which has the largest number of

ambulatory visits of IDV seropositive individuals and serves the majority of
HIV+ women in Rhode Island.
2. Stanley Street Treatment and Resources, which provides primary care for the
indigent and intravenous drug using population in the greater Fall River
Massachusetts area.
3. Veterans Affairs Medical Center in Providence RI, which currently provides
care to approximately 60 IDV seropositive men.

7

Data Collection
Patients meeting the above criteria who visited one of the three sites were asked to fill
out a standardized questionnaire. The patients were told that the questionnaire was
about how they think and feel about the HIV related medications that they were
taking, and about different strategies that people use to take their medications. They
had the choice to complete it at home and mail it in return to the clinic, or complete it
right at the clinic. They were told they would receive a gift certificate of $20 after
they had turned in the questionnaire. The data was collected during the year 19961997. After completion of the questionnaire, a subset of patients (n=86) were
randomly selected to receive a 30-day supply of their prescribed medication in a vial
with Medication Event Monitoring System (MEMS) TrackCap™ (APREX
Corporation, Union City, California). A second appointment was scheduled for 1
month later, and data from the MEMS TrackCap were read using a MEMS-4
Communicator. All patients were offered a $50 gift certificate for their participation
in the MEMS portion of the study.
The survey questionnaire administered to patients included data on demographics,
living arrangements, education, employment, income, insurance, social support, side
effects and a psychological measurement scale. It was a self-reported questionnaire.
The answers were checked for completeness.
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Measures and Variables Assessed
The questionnaire included the following questions:
•

Demographics: age, gender, race, years of education, income, insurance,
number in household, current health status and employment.

•

Mood status.

•

Economic status: cost of regimen, insurance coverage.

•

Physical functioning: weeks in bed, hospitalization.

•

Medical status: self reported disease and medication history, # of doses
missed.

•

Coping: coping with normal work outside and at home.

•

Social support: support from family and friends and other health care
providers.

•

Side effects.

Sensitivity and Specificity were calculated for the following self-report measures.
1. Number of dosed missed in past one month.
2. Number of doses missed in past three months.
3. Medication adherence scale.
4. Temptation to skip medication scale.

I. Number of doses missed in past one month: This was a self-reported answer to the
question "how many doses of medication have you missed in the past one month".
Higher numbers indicate worse compliance.

9

2. Number of doses missed in past three months: This was a self-reported answer to
the question "how many doses of medication have you missed in the past three
months".
Higher numbers indicate worse compliance.
3. Medication Adherence Scale: MAS or Medication Adherence Scale is a previously
validated scale to measure compliance [26]. It contains six questions that are answered
"yes" or "no". Each patient scored two for every 'yes' and one for every 'no'. A
positive response indicates a problem with adherence and the total score range from 612, with higher scores indicating poorer adherence. The following questions are
included in this scale:
•

During the last 3 months, have you ever stopped taking your protease
inhibitor/ antiretroviral medication because you felt better?

•

During the last 3 months, have you ever stopped taking your protease
inhibitor/ antiretroviral medication because you felt worse?

•

During the last 3 months, have you ever forgotten to take your protease
inhibitor/ antiretroviral medication?

•

During the last 3 months, have you at times been careless about taking your
protease inhibitor/ antiretroviral medication?

•

During the last 3 months, have you ever taken less of your protease inhibitor/
antiretroviral medicine than your doctor prescribed because you felt better?

•

During the last 3 months, have you ever taken less of your protease inhibitor/
antiretroviral medicine than your doctor prescribed because you felt worse?

10
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4. Temptation to skip medication scale: This scale was developed to measure selfreported likelihood of non-compliance (Willey, C et al., manuscript in progress). The
items on the temptation scale were based upon predictors of compliance from the
literature and included situations that might affect the taking of protease inhibitors or
anti-retrovirals as directed. Responses for each situation rated how tempted the patient
would be to skip their protease inhibitor medication. The responses were measured on
a five-point Likert scale (continuous) with l=not tempted to 5=extremely tempted.
A few of the items on temptation to skip medication scale include:
•

When you feel good and think you don't need it.

•

When you are anxious about the side effects.

•

When you want to save on the cost of medication.

•

When your doctor doesn' t seem interested in whether you take your

medication.
•

When you start feeling better.

3 categories were developed:
a. Temptation to skip medication due to side effects
•

When you are anxious about side effects.

•

When you experience minor side effects.

•

When you feel you should give your body a rest.

•

When you worry that the chemicals in the medication might harm your body.
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b. Temptation to skip medication due to lack of support
•

When your family and friends don't seem concerned enough about your

condition.
•

When your doctor doesn't seem concerned enough about your condition.

•

When your insurance doesn ' t cover the cost of your medication.

•

When you lose confidence in your doctor.

c. Temptation to skip medication when feeling good

{

•

When you feel good and think you don't need it.

•

When your medical condition doesn't seem that bad.

•

When it seems too complex to keep track of all your medications.

•

When you aren ' t sure if the medication is really helping you.

d. Total Scale
Scores on each sub-categories were obtained by adding items under each subscale.
Score on total scale was obtained by summing all the items under all the subcategories.

Variables Used:
The variables were coded as follows :

Demographic characteristics
Age: Categorical (AGEGRP)
~

25yrs: 1

26-35yrs: 2

12

(
36-45yrs: 3
46-55yrs: 4

Sex: Categorical
Male: M
Female: F

Race: Categorical
White, non-Hispanics: 1
Hispanics: 2
African American: 3
Native American: 4

(

Asian: 5
Others: 6

Years of education: Categorical (EDU)
>12yrs: 1
12yrs: 2
13-15yrs: 3
16+yrs: 4

Annual Income: Categorical
Less than $15,000: 1
$15,000 to $24,000: 2
$25,000 to $34,000: 3
$35,000 to $44,000: 4

13

$45,000 to more: 5

Current health status: Categorical
Excellent: 1
Very good: 2
Good: 3
Fair: 4
Poor: 5

Insurance: Categorical
No insurance: 1
Insurance: 2

Employment status: Categorical (EMP)
Employed: 1
Not employed: 2

T-Cell count last tested: Categorical
>500: 1
201-500: 2
50-200: 3
Less than 50: 4
There were three different classes of drugs prescribed to the patients, DRUG 1,
DRUG 2 and DRUG 3. DRUG 1 mostly comprised of protease inhibitors and
DRUG 2 mostly comprised of ART and DRUG 3 comprised of anti-infectives.
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Total Population on Protease Inhibitors (Pl): All the patients who were
prescribed protease inhibitor in DRUG 1 (thrice day) class comprised the total
patient population on protease inhibitor. This set of patients was used for further
analysis of patient population PI (n=82).

Total Population on Anti-retrovirals (ART): All the patients who were prescribed
anti-retrovirals in DRUG 2 class comprised the total patient population on ART.
This set of patients was used for further analysis of patient population ART
(n=66). All the drugs in DRUG 2 class had different dosing schedule ranging from
2 times a day to 5 times a day, so the measures number of doses missed in past one
month and number of doses missed in past three months were difficult to calculate
for patient population on ART and so were not used for them.

Statistical Analysis:
Descriptive statistics were calculated for all self-report measures of compliance
and for i\IBMS data. The data was analyzed using the Statistical Analysis System
(SAS) Version 8.0 on IBM compatible computer at the University of Rhode
Island.

Compliance coding strategies

A) Coding of self-report measures:
For all the measures 0 =Compliant and 1= Non-compliant.
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1. Number of dosed missed in the past one month:
This was converted to % of doses missed in the past one month (OM) using the
following formula:
OM= [(90 - #of dosed missed in the past one month) I 90]

* 100

This measure was divided into two sub measures to test compliance at two
different cutoffs

~

80% compliance and ~ 90% compliance.

OMI:

~

80% Compliance

OM2:

~

90% Compliance

OMJ: Categorical
~

80%: 0

<80%: 1
OM2: Categorical
~

90%: 0

<90%: 1
2. Number of doses missed in the past three months: This was converted to %
of doses missed in the past three months (TM) using the following formula:
TM= [(270 - #of dosed missed in the past three months) I 270]

* 100

This measure was divided into two sub measures to test compliance at two
different cutoffs ~ 80% compliance and ~ 90% compliance.
TMI:

~

80% Compliance

TM2:

~

90% Compliance
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TMJ: Categorical
~

80%: 0

<80%: 1
TM2: Categorical
~

90%: 0

<90%: 1
3. Medication Adherence Scale (MAS): This scale consisted of six questions to be
answered yes/no. Where the patient scored 1- for every yes and 2- for every no. With
the total score ranging from 6 to 12.
This scale was recoded as 1 for every 'yes' and 0 for every 'no' to get the range from
0-6.
Total Score =Sum of the scores for all 6 answers.

For patient population Protease inhibitors: The measure MAS was further divided
in three sub-measures (PIMl, PIM2 and PIM3) to help determine the optimal scoring
procedure for this self-report measure.

PIMJ: Categorical
MAS Scores: 0= 0
MAS Scores: 1-6= 1

PIM2: Categorical
MAS Scores: 0 and 1= 0
MAS Scores: 2-6=1

PIM3: Categorical
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MAS Scores: 0, 1and2 =0
MAS Scores: 3-6 = 1

For patient population on Antiretrovirals: The measure MAS was further divided in
three sub-measures (AVMl, AVM2 and AVM3) to determined the optimal scoring
procedure for this self-report measure.

A VMJ: Categorical
MAS Scores: 0= 0
MAS Scores: 1-6= 1
A VM2: Categorical
MAS Scores: 0 and 1= 0
MAS Scores: 2-6 = 1
A VM3: Categorical
MAS Scores: 0, 1 and 2=0
MAS Scores: 3-6 = 1
4. Temptation to skip medication scale: The responses for this scale were measured
on a five point Likert scale (continuous) with 1= not tempted to 5= extremely
tempted.
This scale was further divided into two sub-scales:
a. Temptation to skip medication 12 scale (TEMP 12): This scale included the twelve
questions listed on pages 11-12. The total score ranged from 12 to 60 (each question
contributing 1-5 points) with higher score indicating worse compliance.
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b. Temptation to skip medication 13 scale (TEMP 13): This scale included the twelve
questions listed in the above section with the addition of the question "When you feel
like giving up" . The purpose of including this particular question was to test the
importance of this variable in measuring compliance.
The total score ranged from 13 to 65 with higher score indicating worse compliance
with each question contributing 1-5 points.

For patient population Pl: TEMP 12 and TEMP 13 scales were coded as follows on
the bases of the scores obtained. The cutoffs were determined on the basis of
adequate distribution of patients in each category.

Pl12Tl: Categorical
Temp 12 Score: 12 = 0
Temp 12 Score: 13-60 = 1

P113Tl: Categorical
Temp 13 Score: 13

=0

Temp 13 Score: 14-65 = 1

For patient population ART: TEMP 12 and TEMP 13 scales were coded as follows
on the bases of the scores obtained. The cutoffs were determined on the basis of
adequate distribution of patients in each category.

A V12Tl: Categorical
Temp 12 Score: 12 = 0
Temp 12 Score: 13-60 = 1
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A V12T2: Categorical
Temp 12 Score: 12 and 13

=0

Temp 12 Score: 14-60 = 1

A V12T3: Categorical
Temp 12 Score: 12, 13 and 14 =0
Temp 12 Score: 15-60 = 1

A Vl3Tl: Categorical
Temp Score: 12 =0
Temp Score: 13-65 = 1

A Vl3T2: Categorical
Temp 13 Score: 12 and 13

=0

Temp 13 Score: 14-65 = 1

AV13T3: Categorical
Temp 13 Score: 12, 13 and 14 = 0
Temp 13 Score: 15-65 = 1

B) Coding of MEMS measures:
For all the MEMS measures 0 indicates compliant and 1 indicates non-compliant.
Two MEMS measures were used as different gold standards. One indicating

~

80%

doses taken as prescribed, the other indicating~ 90% of doses taken as prescribed.

MEMSl (Gold standard I): Tested the compliance at 80% cutoff. This measure was
coded as follows:
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MEMSl: Categorical
~

80%= 0

<80%= 1

MEMS2 (Gold standard II): Tested the compliance at 90% cutoff. This measure was
coded as follows:

MEMS2: Categorical
~

90%= 0

<90%= 1
Comparison of self-report measures with MEMS:
For each patient a comparison of compliance behavior was made between self-report
measures and MEMS reported compliance. True positive (A) indicated both the selfreport and the MEMS gold standard show compliance. False positive (B) indicated
the self-report indicates compliance but the MEMS gold standard indicates
noncompliance. False negative

(C)

indicated that the self-report indicates

noncompliance but MEMS gold standard indicates compliance. True negative (D)
indicated that both the self-report and MEMS gold standard both indicate
noncompliance.
Example considering Gold standard I (MEMS

~

80% doses taken) and Self-report

measure # 1 (% of doses taken in the past one month):
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MEMS

SELF-REPORT

~80%

<80%

Compliant

Compliant

~

80% of doses taken in
the past one month
< 80% of doses taken in
the past one month

A

B

c

D

Where A= True positive, B= False positive, C= False negative and D= True negative.
Sensitivity and Specificity were calculated for all the measures. Sensitivity is defined
as the proportion of the population who truly has the characteristics that are correctly
classified as having it.

Sensitivity=
(true-positive)
=
(true positive+ false-negative)

A
(A+c)

Specificity is defined as the proportion of the population who truly do not have the
characteristic that are correctly classified as not having it.

Sensitivity=
(true-negative)
=
(true negative+ false-positive)

D
(B+D)

Sensitivity and Specificity are the quantitative indices of the accuracy of measurement
[27].
The overall agreement between the self-report and MEMS was measured using kappa
statistics. Kappa statistics an index of reliability. Reliability, or reproducibility, refers
to the extent to which results of a measurement can be replicated [2 7,23].
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Kappa coefficient (K) = Observed agreement - Expected agreement
1- Expected agreement

The kappa coefficient is an important characteristic of correcting for the chance
agreement that would be expected to occur if two classifications were completely
unrelated. Failure to take into account chance agreement can lead erroneous
conclusions about the quality of measurement. Kappa performance was analyzed using
standard nomenclature <0 poor; 0 to 0.2 slight; 0.21 to 0.4 fair; 0.41 to 0.6 moderate;
0.61 to 0.8 substantial; 0.8 to 1 almost perfect [27 ,23].

(
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RESULTS
A total population of 145 patients was enrolled in the original study. A sub-population
of 86 patients participated in the MEMS monitoring. Demographic data is shown in
table A. Eighty two of these were on protease inhibitors (Pl), and 66 patients were on
anti-retroviral therapy (ART). The median age was 38.5 years and age ranged from
26-55 years. White-non-Hispanics represented 80% of the 86 patient population,
Hispanics 3.5%, African American 3.5% and Native Americans 6%. Most of the
patients were uninsured (95%) and 58% were unemployed. Eighty six percent had at
least high school education. More than half of the study population had an annual
income of less than $15,000. Thirty-five percent had very good health status and 43%
had good health status.
I. For Population on Protease Inhibitor:

A) Comparison between MEMS and % of doses missed in the past one month.
For this measure n=68. This measure was compared with two different compliance
levels i.e. • 80% compliance and • 90% compliance as determined by MEMS.
Table 1-2 and Tables 12-13: Shows the agreement between compliance as measured
by MEMS and by self-report % doses missed in the past one month. All the patients
(68/68) were classified as compliant

for~

80% compliance# of doses missed in the

past one month. In contrast, only (47/68) 69% were classified as

~

80% compliance

level by MEMS . This shows a clear indication of overestimation of adherence by selfreport.
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The highest sensitivity i.e.100% was recorded for both ;;::: 80% compliance number of
doses missed in the past one month and ;;::: 90% compliance of doses missed in the past
one month, at both 80% and 90% cutoffs for MEMS. The specificity remained low, at
all the above levels indicating a low accuracy of the measure. The value of kappa was
0.00 and 0.13 for >80% number of doses missed in the past one month and >90%
number of doses missed in the past one month respectively at >80% compliance
determined by MEMS and 0.00 and 0.06 for >80% # of doses missed and >90%
number of doses missed respectively at >90% compliance determined by MEMS
indicating low reliability of the measure.
B) Comparison between MEMS and % of doses missed in the past three months.

For this measure n=68. The measure was studied at 2 different compliance levels i.e.
>80% compliance and >90% compliance.
Table 3-4 and Tables 14-15: Shows the agreement between MEMS and % doses
missed in the past three months. 99% of the population was classified as compliant at
>90% number of doses missed in the past three months, in contrast to 69% by MEMS
report.
The highest sensitivity i.e.100% was recorded for both >80% compliance number of
doses missed in the past three months and >90% compliance number of doses missed
in the past three months, at both 80% and 90% cutoffs for MEMS. The specificity
remained low, at all the above levels indicating a low accuracy. The value of kappa
was 0.00 and 0.05 for >80% number of doses missed in the past three months and
>90% number of doses missed in the past three months respectively at >80%

25

compliance determined by MEMS and 0.00 and 0.03 for >80% number of doses
missed in the past three months and >90% number of doses missed in the past three
months respectively at >90% compliance determined by MEMS indicating low
reliability of the measure.

C) Comparison between MEMS and Medication Adherence Scale (MAS).
For this measure the total population was n=67 . Three different cutoff scores were
used to determine which was the most useful.

Table 5-7 and Tables 14-16: Shows the agreement between MEMS and Medication
Adherence Scale. The highest sensitivity was seen when the score of 0,1 and 2 on
MAS was set as compliant and the score 3 or more as noncompliant for both >80%
and >90% of doses taken as measured by MEMS . The highest specificity was
observed when the score of 0 was set as compliant and the score of lor more as noncomplaint

at both 80% and 90% cutoff values for MEMS. The agreement with

MEMS data was highest when scores of 0, 1 and 2 was set as compliant and 3 or more
as non-complaint (K=0.37) for >80% compliance MEMS and when the score of 0
was set as complaint and 1 or more as non-compliant (K=0.31) for >90% compliance
MEMS indicating fair reliability.

D) Comparison between MEMS and Temptation to skip medication scale 12
(TEMP12).
For this measure the total population was n=64.

Table 8 and 17: Shows the agreement between MEMS and Temptation to skip
medication scale 12. The total score on the scale ranged from 12-60. Two different
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cutoff scores were used to determine the most useful level. When the cutoff score of
12 was set as complaint and 13 and more as non-compliant, the sensitivity remained
i.e. 0.52 for both >80% compliance and >90% compliance MEMS, but the specificity
was higher at the >80% cutoff for MEMS (0.61) as compared to >90% cutoff for
MEMS (0.55). This measure showed a low reliability at kappa values of 0.06 (>80%
compliance MEMS) and 0.11 (>90% compliance MEMS).

E) Comparison between MEMS and Temptation to skip medication scale 13
(TEMP13).
For this measure the total population was n=64.

Table 9 and 18: Shows the agreement between MEMS and Temptation to skip
medication scale 13. The total score on the scale ranged from 13-65. Two different
cutoff scores were used to determine the most useful level. When the cutoff score of
13 was set as complaint and 14 and more as non-compliant, the sensitivity remained
the same i.e. 0.52 for both >80% compliance and >90% compliance MEMS, but the
specificity was higher at the >80% cutoff for MEMS (0.61) as compared to >90%
cutoff for MEMS (0.55). This measure showed a low reliability at kappa values of
0.06 (>80% compliance MEMS) and 0.11 (>90% compliance MEMS).

For patients on Anti-retroviral therapy:
F) Comparison between MEMS and Medication Adherence Scale
(MAS).

For this measure the total population was n=62. Three different cutoff scores were
used to determine which one was the most useful.
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Table 19-21 and Tables 27-29: Shows the agreement between MEMS and
Medication Adherence Scale. The total score on the scale ranged from 6-36. The
highest sensitivity of 0.98 was seen when the score of 0, 1 and 2 was set as
compliant and the score of 3 and more as non-compliant for both >80% and >90%
of doses taken as measures by MEMS. The highest specificity was observed when
the score of 0 was set as compliant and 1 or more as non-complaint for both 80%
and 90% cutoff values for MEMS. The agreement with MEMS was highest when
the score of 0 was set as complaint and 1 or more as non-complaint (K=0.16) for
>80% compliance MEMS and (K=0.33) for >90% compliance MEMS indicating
fair reliability.

G) Comparison between MEMS and Temptation to skip medication scale 12
(TEMP12).
For this measure the total population was n=64. Three different cutoff scores were
used to determine which one was the most useful.

Table 22-24 and Tables 30-32: Shows the agreement between MEMS and
Temptation to skip medication scale 12. The total score on the scale ranged from
12-60. The highest sensitivity of 0.61 and 0.66 was seen when the score of 12, 13
and 14 was set as compliant and the score of 15 and more as non-compliant for
both >80% and >90% of doses taken as measured by MEMS respectively. The
highest specificity of 0.68 and 0.64 was observed when the score of 12 was set as
compliant and 13 or more as non-compliant for both 80% and 90% cutoff values
for MEMS respectively. The agreement with MEMS was highest when the score
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of 12 and 13 was set as complaint and 14 or more as non-compliant i.e. K=0.16 for
>90% compliance MEMS.

H) Comparison between MEMS and Temptation to skip medication scale 13
(TEMP13).
For this measure the total population was n=56. Two different cutoff scores were
used to determine which one was the most useful.

Table 25-26 and Tables 33-34: Shows the agreement between MEMS and
Temptation to skip medication scale 13. The total score on the scale ranged from
13-65. The highest sensitivity of 0.57 and 0.61 was seen when the score of 13 and
the score of 14 was set as compliant and the score of 15 and more as noncompliant for both >80% and >90% of doses taken as measured by MEMS
respectively. The highest specificity of 0.68 and 0.64 was observed when the score
of 13 was set as compliant and 14 or more as non-complaint for both 80% and
90% cutoff values for MEMS respectively. The agreement with MEMS was
highest at the when the score of 13 and 14 was set as compliant and 15 or more as
non-complaint i.e. K=0.21 for >90% compliance, indicating fair reliability of the
measure at this particular cutoff.
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DISCUSSION
There is little debate that adherence to treatment recommendations has a major impact
on health outcomes and the cost of health care. For medications, the health effect of
deviations from recommended therapy is a function of the pharmacological properties
of the medication prescribed. The methods used to estimate adherence in research or
practice must be sensitive variations in adherence that meaningfully affect health
outcomes.
Formal validation of the many alternative methods of adherence assessment has not
been extensive. No published study has evaluated all these measures against electronic
monitoring in the same population.
In this study we examined the accuracy of various self-report measures of adherence
with electronically monitored adherence.

Number of doses missed in past one month:
The results for the second measure i.e. numbers of doses missed in the past three
months were very much similar to the first measure. The sensitivity was 100%
indicating that the complaint patients were correctly classified, as being complaint, at
the same time the specificity was zero, indicating that the non-compliant patients were
incorrectly classified, as complaint. Therefore there was only a slight agreement
between the compliance reported using this measure and MEMS report, indicating low
reliability of this measure.
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Number of doses missed in the past three months:
The results for the second measure i.e. numbers of doses missed in the past three
months were very much similar to the first measure. The sensitivity was 100%
indicating that the complaint patients were correctly classified, as being complaint, at
the same time the specificity was zero, indicating that the non-compliant patients were
incorrectly classified as complaint. Therefore there was only a slight agreement
between the compliance reported using this measure and MEMS report (K= 0.05 and
0.03) indicating low reliability of this measure.

Medication Adherence Scale:
The third measure MAS was studied at three different cutoff scores, for both subsets
of population i.e. patients on PI and patients on ART.
In the PI population when the MAS was coded as, score of 0 as compliant and 1 or

more as non-compliant, it underestimated adherence as compared to MEMS report and
showed low sensitivity and high specificity. This indicated that the non-compliant
patients were correctly classified as non-adherent, but at the same time the all the
compliant patient were not correctly classified as compliant. Both the sensitivity and
specificity were higher at

~

90% compliance MEMS then at

~

80% compliance

MEMS, indicating greater accuracy at higher cutoff compliance values. The
agreement of this measure was better with
compared

to~

~

90% compliance MEMS (K=0.26) as

80% compliance MEMS (K=0.31), indicating better reliability at 90%

cutoff i.e. more stringent conditions. When the MAS was coded as, score of 0 and 1 as
compliant and 2 or more as non-compliant, it showed good sensitivity compared to
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specificity, indicating poor accuracy of this method, also greater accuracy was seen at
90% cutoff as compared to 80%. The agreement with MEMS was fair (K=0.22) when
compared with

~

80% compliance MEMS and (K=0.25) with

~

90% compliance

MEMS.
When the MAS was coded as, score of 0, 1 and 2 as compliant and 3 or more as noncompliant, it showed a very high sensitivity and a low specificity leading to
overestimation of compliance. The reliability and accuracy results were opposite at
this level of compliance on MAS, the agreement at
(K=0.15) was lower than

at~

~

90% compliance MEMS

80% compliance MEMS, also the accuracy was lower at

90% cutoff compared to 80%. This indicated that as compliance level become less
stringent the accuracy and reliability of the measure decreases.
In the patients with ART, when the MAS was coded as, score of 0 as compliant and 1

or more as non-complaint, it showed a higher sensitivity as compared to specificity.
Both the sensitivity and specificity was higher at

~

90% compliance MEMS then at

80% compliance MEMS. The agreement of this measure with
MEMS (K=0.33) was greater then

with~

~

~

90% compliance

80% compliance MEMS (K=0.16). When

the score of 0 and 1 was coded as compliant and 2 or more as non-compliant, it
showed higher sensitivity and lower specificity as compared to the score of 0 as
compliant and 1 or more as non-complaint. When the MAS scale was coded as, score
of 0,1 and 2 as compliant and 3 or more as non-compliant, the measure showed
highest sensitivity as compared to the other two cutoffs. A higher sensitivity was
observed at 90% cutoff MEMS and compared with 80% cutoff MEMS . The reliability
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of this measure was similar both at

~

90% compliance MEMS and

~

80% compliance

MEMS i.e. 0.15.

Temptation to skip medication scale 12:
In patients on PI, when the TEMP 12 scale was coded as, score of 12 as compliant and
13 or more as non-complaint this measure showed average sensitivity and specificity
indicating fair accuracy of this measure, similar results were seen for both 80% and
90% cutoff MEMS. But according to the kappa statistics agreement of this measure
with MEMS was only slight indicating a poor reliability (K=0.11 and 0.06).
For patients on ART, this measure was studied at three different cutoffs to determine
which one is more useful. When the TEMP 12 scale was coded as, score of 12 as
(

compliant and score of 13 or more as non-complaint, it showed lower sensitivity as
compared to specificity. Indicating that the compliant patients were wrongly
categorized as non-compliant. Thus indicating poor accuracy. There was a slight
agreement with MEMS report both at

~

80% compliance (K=0.16) and

~

90%

compliance.
When the TEMP 12 scale was coded as, score of 12 and 13 as complaint and 14 or
more as non-compliant, it showed average sensitivity and specificity, at

~

90%

compliance MEMS indicating good accuracy of this method. But the agreement with
MEMS was slight both at 80% (0.19) and 90% cutoff (K=0.16). When the TEMP 12
scale was coded as score of 12, 13 and 14 as complaint and 15 or more as noncompliant, the reliability at
compared to

~

~80%

compliance MEMS (K=0.18) was slight as

90% compliance MEMS (K=0.21), these kappa values indicated fair

33

agreement between the two measures i.e. temptation to skip medication scale and
MEMS reported compliance. The sensitivity and specificity were higher at this level
as compared to other two cutoffs.

Temptation to skip medication scale 13:
In patients on PI when the TEMP 13 scale was coded as, score of 13 as complaint and
14 or more as non-complaint, the measured showed average sensitivity and specificity
indicating fair accuracy of this measure. Similar results were seen for both 80% and
90% cutoff MEMS at this cutoff value on TEMP 13 scale. At the same time the
agreement of this measure with MEMS was only slight indicating a poor reliability.
There was no difference in both the accuracy and reliability of temptation to skip
medication 12 scale and temptation to skip medication 13 scale at both

~

80% and

~

90% compliance measures by MEMS for this particular cutoff.
For patients on ART this measure was studied at two different cutoffs to determine
which one was more useful. When the TEMP 13 scale was coded as, score of 13 as
compliant and 14 or more as non-complaint, it showed low sensitivity as compared to
specificity. This indicated that the compliant patients were wrongly categorized as
non-compliant. Thus indicating low accuracy. There was only a slight agreement
between the MEMS reported compliance and this measure at both
MEMS (K=0.17) and

~

~

80% compliance

90% compliance MEMS (K=0.18) according to the kappa

statistics.
When the TEMP 13 scale was coded as, score of 13 and 14 as compliant and 15 or
more as non-complaint, it had average sensitivity and specificity (0.61), at

34

~

90%

compliance MEMS indicating good accuracy of this method. The agreement with
MEMS was fair (0.21) at

~

90% compliance MEMS indicating average reliability.

There was only slight agreement with MEMS report at 80% compliance MEMS
(0.18).
The ideal measure of compliance is the one, which has both, good sensitivity and
specificity. For the patients on PI, MAS indicated to be a good measure of compliance.
When the score was set as 0 as complaint and 1 or more as non-compliant, it showed
both good accuracy and fair reliability. Temptation to skip medication had good
accuracy but only slight reliability.
For patients on ART, good accuracy and reliability was seen only at

~

90%

compliance MEMS. MAS subscale (score of 0 as complaint and 1 or more noncompliant) had good sensitivity and specificity and also average reliability.
Temptation to skip medication scale 13 indicated good accuracy at the same time had
fair reliability.

Limitations

Generalizability: The study population was not randomly selected. This puts
limitation on extrapolating the results for the entire population. The results of this
study do not demonstrate the extent of discrepancies between the self-report and
electronic measure of adherence as previously demonstrated in the literature. There are
two possible explanations for these findings. First patients in this study were asked to
document unintentional opening of their MEMS cap on the blank calendar dispensed
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to them at the baseline. As a result, some patients documented missed doses or late
doses, which may have increased their recall and self-report of non-adherence over
previous month. Second, the adherence findings from the study are from a young,
educated, and motivated population with very high degree of adherence, according to
dose percentage calculations. It is possible that self-report, in general, may exceed
MEMS report to a large extent in a markedly nonadherent population and to a lesser
degree in a very adherent patient group.
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CONCLUSION
The objective of this study was to test the sensitivity, specificity and reliability of
various self-report measures , considering MEMS report as the standard.
Self-reported number of doses missed in the past one month and number of doses
missed in the past three months overestimated adherence as compared to MEMS
report. Both these self-report measures showed high sensitivity and low specificity,
which indicated low accuracy of this measure. A probable reason for low accuracy
may be recall memory errors such as forgetting (underreport) and telescoping
(overestimation).
It is also seen that in comparison to number of doses missed in the past one month,

number of doses missed in the past three months had even lower accuracy and
reliability, though not very significant. This might be due an even greater the recall
bias, as the memory of the person becomes weaker over long period of time.
These results were contradictory to a published report which found reported that selfreports were more accurate measures than when number of missed doses was used to
measure compliance (Chesney et al., 1999).
Medication Adherence Scale was divided into three sub-categories to access
compliance at various levels. It was observed that as the criteria for assessment
became less stringent, more non-compliant patients were incorrectly categorized as
compliant leading to decrease in the accuracy of the method. The reliability also
decreased simultaneously.
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Higher accuracy and reliability was obtained at the more (higher) stringent levels of
compliance and MEMS

~

90% compliance as compared with others.

Overall this measure showed a fair agreement with the MEMS report at all higher
cutoff points (stringent conditions). The reliability and the accuracy of this measure
were better in the PI population than in the ART population.
Temptation to skip medication scale was also broken down into sub categories to test
compliance at various levels. Similar results as those for MAS were obtained, except
for temptation to skip medication scale 13 (Score of 13 coded as compliant and 14 or
more as non-compliant) were there was an increase in the reliability along with the
increase in sensitivity and decrease in specificity. This might be due to setting up very
high (stringent) levels of compliance, that even most of the compliant patients were
classified as non-complaint.
The addition of the additional question in temptation to skip medication scale 13 did
not make a significant difference in the assessment of compliance. The results of these
studies regarding the accuracy and reliability of self-report measures of medication
adherence are disappointing,

particularly given the

reliance on

self-report

methodology among the clinical and research communities.
The overall results of all the self-report measures were consistent with the literature on
compliance that self-report methods consistently overestimate patient adherence
(Cramer et al., 1989; Waterhouse et al., 1993).
The study found that measuring compliance on continuous scales like MAS or
temptation to skip medication scale, where the patients were asked about their general
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attitude towards the medication regimen, are more accurate and reliable measures to
detect compliance as compared with number of doses missed. Therefore, these scales
could be further developed in future research to yield better measures to detect
compliance.
In general it was seen for all the measures, that when the criteria for compliance was
set more stringent, it gave more accurate and reliable results.
Additional studies will be required to replicate these findings in other HIV
populations.
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TABLE A: Demographics of population used N=86
Dem02ra_p_hics
Age
>= 25 yrs
26-35 yrs
36-45 yrs
46-55_.r_rs
SEX
Males
Females
Race
White, non-Hispanics
Hispanics
African American
Native American
Asian
Others
Education
> 12 yrs
12 yrs
13-15 yrs
16 +yrs

r

Annual Income
Less than $15,000.
$15000 to $24,000.
$25,000 to $34,000.
$35,000 to $44,000.
$45,000 or more
Current health status
Excellent
Very Good
Good
Fair
Poor
T-Cell count
<500
201-500
50-200
Less than 50
EmJ!loyment Status
Employed
Unem_p_l«!Y_ed
Insurance
No insurance
Some insurance

Mean

snT

Mintf

Maxttt

0(0%)
31 (36.05%)
33 (38.37%)
22 _(25.58°/tl_

2.8953

0.7825

2.0000

4.0000

75 (87.21%)
11_(12.79°/tl_

-

-

-

-

69 (80.23%)
3 (3.49%)
3 (3.49%)
6 (6.98%)
0(0%)
5 (5.81%)

1.6744

1.5219

1.0000

N_(o/tl_

14 (16.28%)
34 (39.53%)
26 (30.23%)
12 (13.95%)

1.0000

2.4186

0.9262

1.0000

4.0000

2.0121

1.4271

1.0000

5.0000

9 (10.47%)
30 (34.88%)
37 (43.02%)
10 (11.63%)
0_(00/.tl_

2.5581

0.8346

1.0000

4.0000

20 (23.81%)
36 (42.86%)
23 (27.38%)
5_{5.95°/tl

2.1547

0.8572

1.0000

. 4.0000

36 (41.86%)
50_(58.14 %1

1.4186

0.4962

1.0000

2.0000

82 (95.35%)
4_(4.65%l

1.0465

0.2118

1.0000

2.0000

45 (54.88%)
17 (20.73%)
5 (6.10%)
4 (4.88%)
11 _(13.41 o/tl_

snt: Standard deviation.
Mintt: Minimum
Maxttt: Maximum
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Table B:
Self-report measures of adherence for patients on protease inhibitors.

Self-report measures

N

Mean

snt

Mintt

Maxttt

I.

Number of doses missed in past one
month.

72

1.60855

2.48843

0

12

2.

Number of doses missed in past three
months.

71

3.57746

5.38957

0

30

3.

Medication Adherence Scale.

71

1.09859

1.28901

0

6

4.

Tem.ptation to skip medication scale 12

68

16.3235

8.01387

12

60

5.

T~mptation

68

17.7941

8.81748

13

65

Nos.

~
......

snt: Standard deviation.
Min tt: Minimum
Maxttt: M~r.imum

to skip medication scale 13

Table C:
Self-report measure of adherence for patients on anti-retroviral therapy.

Self-report measures

N

Mean

snt

Mintt

Maxttt

1.

Medication Adherence Scale

64

0.8437

0.9955

0

4

2.

Temptation to skip
medication 12

59

15.745

5.2966

12

33

3.

Temptation to skip
medication 13

58

17.086

5.9773

13

38

Nos.

~

N

-

snt: Standard deviation.
Min tt: Minimum
Max ttt: Maximum

...,

TABLED:

Compliance coding strategies for patients on protease inhibitors.

.j:::.

w

Self-re_1>_ort measures
1)% of doses missed in past
one month .
a. OMl
b.OM2
2) % of doses missed in past
3 months.
a. TMl
b. TM2
3) Medication Adherence
Scale (MAS) 0-6
a. PIMl
b. PIM2
c. PIM3
4) Temptation to skip
medication Scale 12 (12-60)
a. PI12TI
5) Temptation to skip
medication Scale 13 (13-65)
b. PI13TI

Coding
O=tc and l=ttNc

N_{_%}_

Mean

snt

Mintt

Maxttt

80%=0 and < 80%= 1.
90%=0 and < 90%= 1.

72
72

0
0.02777

0
0.1654

0
0

0
1

80%=0 and< 80%=1 .
90%=0 and < 90%= 1.

71
71

0
0.01408

0
0.11867

0
0

0
1

0 = 0 and 1+ = 1.
0 and l=O and 2+ = 1.
0,1 and 2= 0 and 3+ = 1.

71
71
71

0.57746
0.30985
0.12676

0.49747
0.46572
0.33507

0
0
0

1
1
1

12 = 0 and 13+ = 1.

68

0.51470

0.50349

0

1

13= 0 and 14+ = 1.

68

0.51470

0.50349

0

1

~
~

~

~

tC= Compliant andTfNc =Non Compliant
SDt: Standard deviation.
Mintt: Minimum
Max ttt: Maximum

.

TABLE E:
Compliance coding strategies for patients on Anti-retroviral therapy.
Coding
O=tc and l=ttNc

N

Mean

snt

Mintt

Maxttt

1) Medication Adherence
Scale (MAS) 0-6
a.AVMl
b.AVM2
c. AVM3

0 = 0 and 1+ = 1.
0 and 1=0 and 2+ = 1.
0,1 and 2= 0 and 3+ = 1.

71
71
71

0.57746
0.30985
0.12676

0.49747
0.46572
0.33507

0
0
0

1
1
1

2) Temptation to skip
medication Scale 12 (12-60)
a. AV12TI
b. AV12T2
c. AV12T3

12=0andl3+=1.
12 and 13 = 0 and 14+ = 1.
12, 13and14=0and 15+= 1

68

0.51470

0.50349

0

1

3) Temptation to skip
medication Scale 13 (13-65)
a. AV13TI
b.AV13T2
c. AV13T3

13= 0 and 14+ = 1.
13 and 14 = 0 and 15+ = 1.
13, 14 and 15 = 0 and 16+ = 1

68

0.51470

0.50349

0

1

Self-report measures

..j::..
..j::..

tC= Compliant and t1Nc =Non Compliant
SD t: Standard deviation.
Min tt: Minimum
Max ttt: Maximum

'·

TABLE F:
Compliance coding strategies for MEMS data for patients on protease inhibitors.

MEMS Measures

.+:>.

Vl

Coding
O=tc and l=ttNc

N

Mean

snt

Mintt

Maxttt

1) Gold Standard I
MEMS 1

~

80%=0 and< 80%=1.

64

0.34375

0.47871

0

1

2) Gold Standard II
MEMS2

~

90%=0 and < 90%= 1.

64

0.48437

0.50370

0

1

tC= Compliant and ttNc =Non Compliant
snt: Standard deviation.
Mintt: Minimum
Max ttt: Maximum

TABLEG:

Compliance coding strategies for MEMS data for patients on Anti-retroviral therapy.

Coding
O=tc and l=ttNc

N

Mean

snt

Mintt

Maxttt

~

80%=0 and< 80%=1.

64

0.34375

0.47871

0

1

~

90%=0 and < 90%= 1.

64

0.48437

0.50370

0

1

MEMS Measures

1) Gold Standard I

MEMS 1
.,J:::.

°'

2) Gold Standard II
MEMS2

tC= Compliant and ttNc =Non Compliant
snt: Standard deviation.
Mintt: Minimum
Max ttt: Maximum

~

~

TABLEH:
Sensitivity, Specificity and Kappa statistics for various Self-report measures for patients on Protease
inhibitors. ~ 80°/o Compliance by MEMS (Gold Standard I)
Nos.

J_Self-report measures

1

, . #of doses missed in past one month
( ~ 80%=Ct & <80%=ttNC)
# of doses missed in one past month
(~ 90%=C t & <90%=ttNC)
# of dosed missed in past three months
(~ 80%=Ct & <80%dtNC)
# of doses missed in three past month
(~ 90%=C t & <90%=ttNC)
Medication Adherence Scale
(O=Ct & l+=ttNC)
Medication Adherence Scale
(0 & l=Ct & 2+dtNC)
Medication Adherence Scale
(0,1&2=Ct & 3+dtNC)
Temptation to skip medication scale 12
(12=Ct &13+dtNC)
Temptation to skip medication scale 13
(13=Ct &14+=ttNC)

2
3
-+>-....]

4
5
6
7
8
9

C= Compliant
ttNC= Noncompliant

t

Sensitivity

Specificity

Observed
a_g_reemen t
0.69

Kappa

0.00

Expected
a_g_reement
0.69

1.00
1.00

0.10

0.72

0.72

0.13

1.00

0.00

0.69

0.69

0.00

1.00

0.05

0.69

0.71

0.06

0.53

0.80

0.61

0.61

0.26

0.77

0.45

0.67

0.67

0.22

0.96

0.35

0.78

0.78

0.37

0.52

0.61

0.55

0.55

0.11

0.52

0.61

0.55

0.55

0.11

0.00

--.....

TABLE I:
Sensitivity, Specificity and Kappa statistics for various Self-report measures for patients on Protease
inhibitors. ~ 90°/o Compliance by MEMS (Gold Standard

in

Nos.
1
2
3
.i:.

00

4
5

6
7
8
9

I Self-report measures
# of doses missed in past one month
(~ 80%=C t & <80%dtNC)
# of doses missed in one past month
(~ 90%=C t & <90%=ttNC)
# of dosed missed in past three months
(~ 80%=Ct & <80%=ttNC)
#of doses missed in three past month
(~ 90%=C t & <90%=ttNC)
Medication Adherence Scale
(O=Ct & l+=ttNC)
Medication Adherence Scale
(0 & l=Ct & 2+=ttNC)
Medication Adherence Scale
(0,1&2=Ct & 3+=ttNC)
Temptation to skip medication scale 12
(12=C t &13+=ttNC)
Temptation to skip medication scale 13
(13=Ct &14+=ttNC)

C= Compliant
ttNC= Noncompliant

t

Sensitivity

Specificity

1.00

0.00

Expected
a_greement
0.50

Observed
a_g_reement
0.50

Kappa
0.00

1.00

0.06

0.50

0.53

0.06

1.00

0.00

0.50

0.50

0.00

1.00

0.03

0.50

0.51

0.03

0.59

0.73

0.50

0.66

0.31

0.82

0.42

0.50

0.63

0.25

0.94

0.21

0.51

0.58

0.15

0.52

0.55

0.50

0.53

0.06

0.52

0.55

0.50

0.53

0.06

~,

TABLEJ:
Sensitivity, Specificity and Kappa statistics for various Self-report measures for patients on Antiretroviral therapy. ~ 80°/o Compliance by MEMS (Gold Standard I)

Nos.
1
2
.+:>.

\0

3
4
5
6
7
8

Self-report measures

Sensitivity

0.51
Medication Adherence Scale
_{_O=tc & l+=ttNC}
0.83
Medication Adherence Scale
J_O & l=tc & 2+=ttNC)
Medication Adherence Scale
0.98
J_0,1 &2=tc & 2+=ttNC)_
Temptation to skip medication
0.50
scale 12 _(_12=tc &13+=ttNCl
Temptation to skip medication
0.55
scale 12 (12 & 13=tc &14+=ttNC)
Temptation to skip medication
0.61
scale 12 _{_12,13&14=tc&15+=ttNCl
0.51
Temptation to skip medication
scale 13 _{_13=tc &14+=ttNCl
Temptation to skip medication
0.57
scale 13 _(_13 & 14=tc &15+=ttNc_1

' C• COmJ!l11ni

"NC:• NonDOltll'llllflt

Observed

Kappa

0.67

Expected
a2reement
0.48

0.56

0.16

0.29

0.59

0.65

0.13

0.14

0.64

0.69

0.15

0.68

0.48

0.56

0.16

0.63

0.50

0.58

0.16

0.47

0.53

0.56

0.07

0.68

0.48

0.57

0.17

0.63

0.50

0.59

0.18

Specificity

a~eement

TABLE K:
Sensitivity, Specificity and Kappa statistics for various Self-report measures for patients on Antiretroviral therapy.~ 90o/o Compliance by MEMS (Gold Standard II)

Nos.
1
2
3
Vl

0

4
5
6
7
8

Self-report measures
Medication Adherence Scale
J_O=tc & l+=ttNCl
Medication Adherence Scale
J_O & l=tc & 2+=ttNCJ_
Medication Adherence Scale
_i0,1 &2=tc & 2+=ttNCJ_
Temptation to skip medication
scale 12 J_12=tc &13+=ttNCJ_
Temptation to skip medication
scale 12 _Q.2 & 13=tc &14+=ttNCl
Temptation to skip medication
scale 12 J_l2,13&14=tc&l5+=ttNCl
Temptation to skip medication
scale 13 _i13=tc &14+=ttNC1
Temptation to skip medication
scale 13 _Q.3 & 14=tc &15+=ttNCl

t C= Compliant
ttNC= Noncompliant

Sensitivity

Specificity

0.61

0.72

Expected
a_g_reement
0.50

Observed
a_g_reement
0.66

Kappa
0.33

0.88

0.31

0.52

0.61

0.20

1.00

0.14

0.53

0.60

0.15

0.52

0.64

0.50

0.58

0.16

0.59

0.61

0.50

0.60

0.19

0.66

0.50

0.50

0.58

0.16

0.54

0.64

0.50

0.59

0.18

0.61

0.61

0.50

0.61

0.21

Table 1:
Agreement between Gold Standard I

(~

80%, compliance MEMS) and Self-report measure # 1 (~

80%, of doses taken in past one month) for patient population on protease inhibitor.

MEMS
~

~

Vi

SELF-REPORT

80% compliance(~ 80% I
of doses taken in the past
one month)

(~

< 80% compliance
80% f
of doses taken missed the
past one month)

Total

< 80% Noncompliant

80% Compliant

Total

47

I

21

I

68

0

I

0

I

0

47

21

Sensitivity= 47/47
Specificity = 0/21

* 100 = 100%

* 100 = 0%

68

Table 2:
Agreement between Gold Standard

I(~

80°/o compliance MEMS) and Self-report measure# 2 (~

90°/o of doses taken in past one month) for patient population on protease inhibitor.
MEMS
:2:

N

SELF-REPORT

< 80% Noncompliant

Total

90% compliance (~ 90%
of doses taken in the past
one month)

47

19

66

< 90% compliance (~ 90%
of doses missed in the past
one month)

0

2

2

47

21

68

~

Vl

80% Compliant

Total

Sensitivity= 47/47
Specificity = 2/21

* 100 = 100%

* 100 = 10%

Table 3:
Agreement between Gold Standard

I(~

80%> compliance MEMS) and Self-report measure# 3

80°/o of doses taken in past three months) for patient population on protease inhibitor.

MEMS
~

w

SELF-REPORT

Total

80% compliance (~ 80%
of doses taken in the past
three months)

I

47

I

20

I

67

< 80% compliance (~ 80%
of doses missed in the past
three months)

I

0

I

1

I

1

~

Ul

< 80% Noncompliant

80% Compliant

Total

21

47

Sensitivity= 47/47
Speci~city

=

1121

* 100 = 100%

* 100 = 5%

68

(~

Table 4:
Agreement between Gold Standard I(:?: 80°/o compliance MEMS) and Self-report measure# 4 (:?:

90°/o of doses taken in past three months) for patient population on protease inhibitor.

MEMS
~

Total

< 80% Noncompliant

80% Compliant

Vl

.j::..

:?: 90% compliance (:?: 90%
SELF-REPORT

I

47

I

21

I

68

0

I

0

I

0

of doses taken in the past
three months)
~

< 90% compliance (:?: 90%
of doses missed in the past
three months)

Total

..

21

47

Sensitivity= 47/47
Specificity= 2/21

68

* 100 = 100%

* 100 =

10%

Table 5:
Agreement between Gold Standard I(~ 80°/o compliance MEMS) and Self-report measure #5
(Medication Adherence Scale) for patients on Protease Inhibitor.

MEMS
~

80% Compliant

< 80% Noncompliant

Total

Medication Adherence Scale
o = tc

25

4

29

Medication Adherence Scale
1+ = ttNc

22

16

38

Total

47

20

67

Vl
Vl

SELF-REPORT

t C= Compliant
ttNc= Noncompliant

Sensitivity= 25/47

* 100 = 53%

Specificity = 16/20

* 100 = 80%

Table 6:
Agreement between Gold Standard I(:?: 80°/o compliance MEMS) and Self-report measure #6
(Medication Adherence Scale) for patients on Protease Inhibitor.
MEMS
~

Medication Adherence Scale
0 and 1= tc

80% Compliant

< 80% Noncompliant

Total

·~
36

47

11
~

Vl

SELF-REPORT

°'

Medication Adherence Scale
2+ = ttNc

11

9

20

Total

47

20

67

Sensitivity= 36/47
Specificity = 9120
t C= Compliant
ttNC= Noncompliant

* 100 = 77%

* 100 = 45%

-

Table 7:
Agreement between Gold Standard I (~ 80o/o compliance MEMS) and Self-report measure # 7
(Medication Adherence Scale) for patients on Protease Inhibitor.
MEMS
~

< 80% Noncompliant

Total

45

13

58

3+ = ttNc

2

7

9

Total

47

20

67

Medication Adherence Scale
0 1and2= tc

'

Vl

80% Compliant

Medication Adherence Scale

-...]

SELF-REPORT

Sensitivity= 45/47
Specificity = 7120

t C= Compliant
ttNC= Noncompliant

* 100 =

96%

* 100 = 35%

Table 8:
Agreement between Gold Standard I (~ 90°/o compliance MEMS) and Self-report measure #8
(Temptation to skip medication scale 12) for patients on Protease Inhibitor.

MEMS
~

Vl
00

SELF-REPORT

Temptation to skip medication
Scale 12
12 = tc
Temptation to skip medication
Scale 12
13+ = ttNc

Total

t C= Compliant
ttNc= Noncompliant

< 80% Noncompliant

80% Compliant

Total

I

24

I

7

I

31

I

22

I

11

I

33

46

18

Sensitivity== 24146

* 100 = 52%

Specificity:;: 11/18

* 100 = 61 %

64

Table 9:
Agreement between Gold Standard I (~ 90°/o compliance MEMS) and Self-report measure #9
(Temptation to skip medication scale 13) for patients on Protease Inhibitor.

MEMS
~

Vl

\0

SELF-REPORT

Temptation to skip medication
Scale 13
I
13= tc
Temptation to skip medication
I
Scale 13
14+ = ttNc
Total

C= Compliant
ttNc= Noncompliant

t

< 80% Noncompliant

80% Compliant

Total

24

I

7

I

31

22

I

11

I

33

46

18

Sensitivity = 24/46

* 100 = 52%

Specificity= 11/18

* 100 = 61 %

64

---..

Table 10:
Agreement between Gold Standard II(;::: 90o/o compliance MEMS) and Self-report measure# 1 (;:::
80% of doses taken in past one month) for patient population on protease inhibitor.

MEMS
~

I
;::: 80% compliance ( ;:::
80% of doses taken in the
past one month)

O'\

0

< 90% Noncompliant

90% Compliant

Total

34

I

34

I

68

0

I

0

I

0

SELF-REPORT
< 80% compliance (<'. 80%
of doses taken missed the
past one month)

Total

I

34

34

Sensitivity = 34/34
Specificity = 0/34

* 100 = 100%

* I 00 = 0%

68

Table 11:
Agreement between Gold Standard

II(~

90% compliance MEMS) and Self-report measure# 2 (~

90o/o of doses taken in past one month) for patient population on protease inhibitor.

MEMS
~

O'I
......

SELF-REPORT

90% Compliant

< 90% Noncompliant

Total

~

90% compliance (~
90% of doses taken in the
past one month)

34

32

66

< 90% compliance (~ 90%
of doses taken missed the
past one month)

0

2

2

Total

34

34

68

Sensitivity= 34/34
Specificity = 2/34

* 100 = 100%

* I 00 = 6%

Table 12:
Agreement between Gold Standard II(~ 90°/o compliance MEMS) and Self-report measure# 3 (~

80°/o of doses taken in past three months) for patient population on protease inhibitor.

MEMS

< 90% Noncompliant

;;;: 90% Compliant

Total

0\
N

~

80% compliance (~ 80%
of doses taken in the past one
month)

I

34

I

34

I

68

< 80% of doses taken in the
past three months=ttNc

I

0

I

0

I

0

SELF-REPORT

Total

34

34

Sensitivity = 34/34
Specificity = 0/34

* 100 = 100%

* 100 = 0%

68

Table 13:
Agreement between Gold Standard

II(~

90°/o compliance MEMS) and Self-report measure# 4 (~

90o/o of doses taken in past three months) for patient population on protease inhibitor.
MEMS
~

90% compliance c~ 90% I
of doses taken in the past one
month)
~

°'w

90% Compliant

Total

< 90% Noncompliant

34

I

33

I

67

0

I

1

I

1

SELF-REPORT
< 90% of doses taken in the
past three months=ttNc

Total

I

34

34

Sensitivity = 34/34 * 100 = 100%
Specificity= 1/34* 100 = 3%

68

-,

Table 14:

Agreement between Gold Standard II(;:::: 90%> compliance MEMS) and Self-report measure# 5
(Medication Adherence Scale) for patients on Protease Inhibitor.

MEMS
~

< 90% Noncompliant

90% Compliant

Total

0\

.i::.

SELF-REPORT

Medication Adherence Scale
o=tc

I

20

I

9

I

29

Medication Adherence Scale
l+=ttNc

I

14

I

24

I

38

Total

C= Compliant
ttNc= Noncompliant

t

34

33

Sensitivity = 20/34

* 100 = 59%

Specificity= 24/33

* 100 = 73%

67

.....\

Table 15:

Agreement between Gold Standard II(~ 90% compliance MEMS) and Self-report measure# 6
(Medication Adherence Scale) for patients on Protease Inhibitor.

MEMS
~

Medication Adherence Scale
oand 1= tc

°'
V\

SELF-REPORT

Medication Adherence Scale
2+=ttNc

Total

t C= Compliant
ttNc= Noncompliant

90% Compliant

28

I
I

6

< 90% Noncompliant

Total

19

47

I
I

34

I
14

33

Sensitivity= 28/34

* 100 = 82%

Specificity= 14/33

* 100 = 42%

I

20

67

Table 16:

Agreement between Gold Standard II(~ 90%, compliance MEMS) and Self-report measure# 7
(Medication Adherence Scale) for patients on Protease Inhibitor.
MEMS
~

°'°'

< 90% Noncompliant

Total

32

26

58

Medication Adherence Scale
3+=ttNc

2

7

9

Total

34

33

67

Medication Adherence Scale
0 1and2=tc
'
SELF-REPORT

90% Compliant

Sensitivity= 32/34
Specificity = 3317
t C= Compliant
ttNC= Noncompliant

* 100 = 94%

* 100 = 21 %

Table 17:

Agreement between Gold Standard II(~ 90°/o compliance MEMS) and Self-report measure# 8
(Temptation to skip medication scale 12) for patients on Protease Inhibitor.
MEMS
~

°'

-...)

SELF-REPORT

Temptation to skip medication
Scale 12
12=tc
Temptation to skip medication
Scale 12
13+=ttNc
Total

t C= Compliant
ttNC= Noncom pliant

90% Compliant

< 90% Noncompliant

Total

17

14

31

16

17

33

33

31

64

Sensitivity = 17/3 3

* 100 = 52 %

Specificity = 14/31

* 100 = 55%

~

-

Table 18:

Agreement between Gold Standard II (~ 90%> compliance MEMS) and Self-report measure # 9
(Temptation to skip medication scale 13) for patients on Protease Inhibitor.
MEMS
~

0\
00

SELF-REPORT

Temptation to skip medication
Scale 13
I
13=tc
Temptation to skip medication
Scale 13
I
14+=ttNc
Total

t C= Compliant
ttNe= Noncompliant

< 90% Noncompliant

90% Compliant

Total

17

I

14

I

31

16

I

17

I

33

33

31

Sensitivity= 17/33

* 100 = 52%

Specificity = 17/31

* 100 = 55%

64

,..---

-.,

Table 19:

Agreement between Gold Standard I(~ 80°/o compliance MEMS) and Self-report measure# 1
(Medication Adherence Scale) for patients on Anti-retroviral.

MEMS
~

\0
°'

SELF-REPORT

Total

Medication Adherence Scale
o=tc

I

21

I

7

I

28

Medication Adherence Scale
l+=ttNc

I

20

I

14

I

34

Total

t C= Compliant
ttNc= Noncompliant

< 80% Noncompliant

80% Compliant

41

21

Sensitivity = 21/41

* 100 = 51 %

Specificity = 14/21

* 100 = 67%

62

,.,--.

Table 20:

Agreement between Gold Standard I (~ 80°/o compliance MEMS) and Self-report measure # 2
(Medication Adherence Scale) for patients on Anti-retroviral.

MEMS
~
-...)

Medication Adherence Scale
oand 1= tc

0

SELF-REPORT

Medication Adherence Scale
2+=ttNc

Total

80% Compliant

< 80% Noncompliant

Total

15

49

34

I
I

I
7

I

I

6

41

21

Sensitivity= 34/41
Specificity = 6/21
t C= Compliant
ttNC= Noncompliant

* 100 = 83%

* 100 = 29%

I

13

62

Table 21:

Agreement between Gold Standard I(~ 80% compliance MEMS) and Self-report measure# 3
(Medication Adherence Scale) for patients on Anti-retroviral.

MEMS
~

-

80% Compliant

< 80% Noncompliant

Total

-....)

SELF-REPORT

Medication Adherence Scale
o,1and2=tc

I

40

I

18

I

58

Medication Adherence Scale
3+=ttNc

I

1

I

3

I

4

Total

41

21

Sensitivity= 40/47
Specificity= 3/21
Compliant
ttNc= Noncompliant
t C=

* 100 = 98%

* 100 = 14%

62

Table 22:

Agreement between Gold Standard I (~ 80°/o compliance MEMS) and Self-report measure # 4
(Temptation to skip medication scale 12) for patients on Anti-retroviral.

MEMS

< 80% Noncompliant

;;:: 80% Compliant

Total

-....)

N

SELF-REPORT

Temptation to skip medication
Scale 12
12=tc
Temptation to skip medication
Scale 12
13+=ttNC

Total

t C= Compliant
ttNC= Noncompliant

I

19

I

6

I

25

I

19

I

13

I

32

38

19

Sensitivity = 19/38

* 100 = 50%

Specificity = 13/19

* 100 = 68%

57

......

Table 23:

Agreement between Gold Standard I(~ 80°/o compliance MEMS) and Self-report measure# 5
(Temptation to skip medication scale 12) for patients on Anti-retroviral.
MEMS
~

-...)

VJ

SELF-REPORT

Temptation to skip medication
Scale 12
12 andl3=tc
Temptation to skip medication
Scale 12
14+=ttNc

Total

t C= Compliant
ttNC=;o Noncompliant

80% Compliant

Total

< 80% Noncompliant

I

21

I

7

I 28

I

17

I

12

I

38

19

Sensitivity= 21/38

* 100 = 55%

Specificity= 12/19

* 100 = 63%

29

57

-.....

--.....

Table 24:

Agreemeut between Gold Standard I(;?: 80%> compliance MEMS) and Self-report measure# 6
(Temptation to skip medication scale 12) for patients on Anti-retroviral.

MEMS
~

Total

< 80% Noncompliant

80% Compliant

-....)
.j::>.

SELF-REP( 1RT

Temptation to skip medication
Scale 12
12, 13 and 14=tc
Temptation to skip medication
Scale 12
15+=ttNc
Total

I

23

I

10

I

I

15

I

9

I 24

19

57

38

Sensitivity= 23/38 * 100 = 61 %
Specificity = 9/19* 100 = 47%
C= Complian'
ttNc= Noncon pliant
t

33

Table 25:

Agreement between Gold Standard I(~ 80°/o compliance MEMS) and Self-report measure# 7
(Temptation to skip medication scale 13) for patients on Anti-retroviral.

MEMS
~
-....)

Vi

SELF-REPORT

Temptation to skip medication
Scale 13
13=tc
Temptation to skip medication
Scale 13
14+=ttNc

Total

t C= Compliant
ttNc= Noncompliant

< 80% Noncompliant

80% Compliant

Total

I

19

I

6

I

25

I

18

I

13

I

31

37

19

Sensitivity = 19/37

* 100 = 51%

Specificity= 13/19

* 100 = 68%

56

Table 26:

Agreement between Gold Standard I (~ 80%> compliance MEMS) and Self-report measure # 8
(Temptation to skip medication scale 13) for patients on Anti-retroviral.

MEMS
~

-...)

0\

SELF-REPORT

Temptation to skip medication
Scale 13
13and 14=tc
Temptation to skip medication
Scale 13
15+=ttNc
Total

C= Compliant
ttNc= Nonc.:ompliant

t

< 80% Noncompliant

80% Compliant

Total

I

21

I

7

I

28

I

16

I

12

I

28

37

19

Sensitivity= 21/37

* 100 = 57%

Specificity= 12/19

* 100 = 63%

56

Table 27:

Agreement between Gold Standard II(~ 90%> compliance MEMS) and Self-report measure# 1
(Medication Adherence Scale) for patients on Anti-retroviral.

MEMS
~
-..J
-..J

Medication Adherence Scale
o=tc

SELF-REPORT

Medication Adherence Scale
l+=ttNc

Total

t C= Compliant
ttNc= Noncompliant

90% Compliant

< 90% Noncompliant

Total

8

28

20

I
I

I
13

I

33

I
21

29

Sensitivity= 20/33

* 100 = 61 %

Specificity= 21/29

* 100 = 72%

I

34

62

,,---

-.

Table 28:

Agreement between Gold Standard II(~ 90%> compliance MEMS) and Self-report measure h 2
(Medication Adherence Scale) for patients on Anti-retroviral.
MEMS

-..I
00

SELF-REPORT

;;:: 90% Compliant

< 90% Noncompliant

Total

Medication Adherence Scale
o and 1= tc

29

20

49

Medication Adherence Scale
2+=ttNc

4

9

13

Total

33

29

62

Sensitivity = 29/33

* 100 = 88%

Spec.ificity = 9/29 * 100 = 31 %
t C= Compliant
ttNc= Noncompliant

-

Table 29:

Agreement between Gold Standard II(~ 90°/o compliance MEMS) and Self-report measure# 3
(Medication Adherence Scale) for patients on Anti-retroviral.

MEMS
~

< 90% Noncompliant

90% Compliant

Total

-....)

\0

Medication Adherence Scale
0 1and2=tc
'
SELF-REPORT

Medication Adherence Scale
3+=ttNc

Total

I

33

I

25

I

58

I

0

I

4

I

4

33

Sensitivity= 33/33

29

* 100 = 100%

Specificity= 4/29 * 100 = 14%
t C= Compliant
ttNC= Noncompliant

62

- ....

Table 30:

Agreement between Gold Standard II(~ 90%, compliance MEMS) and Self-report measure# 4
(Temptation to skip medication scale 12) for patients on Anti-retroviral.
MEMS
::>:

00
0

SELF-REPORT

Temptation to skip medication
Scale 12
I
12=tc
Temptation to skip medication
Scale 12
I
13+=ttNc
Total

< 90% Noncompliant

90% Compliant

15

I

10

I 25

14

I

18

I 32

28

57

29

Sensitivity= 15/29 * 100 = 52%
Specificity = 18/28 * 100 = 64 %
C= Compliant
ttNC= Nancompliant
t

Total

"'"""'

Table 31:

Agreement between Gold Standard II(~ 90°/o compliance MEMS) and Self-report measure# 5
(Temptation to skip medication scale 12) for patients on Anti-retroviral.

MEMS

< 90% Noncompliant

;:.: 90% Compliant

00

SELF-REPORT

Temptation to skip medication
Scale 12
12 and13=tc
Temptation to skip medication
Scale 12
14+=ttNc
Total

t C= Compliant
ttNc= Noncompliant

Total

I

17

I

11

I

I

12

I

17

I 29

28

57

29

Sensitivity = 17/29

* 100 = 59%

Specificity= 17/28

* 100 = 61 %

28

-,

Table 32:

Agreement between Gold Standard II(~ 90% compliance MEMS) and Self-report measure# 6
(Temptation to skip medication scale 12) for patients on Anti-retroviral.

MEMS
~

00

N

SELF-REPORT

Temptation to skip medication
Scale 12
12, 13 and 14=tc
Temptation to skip medication
Scale 12
15+=ttNc

Total

t C= Compliant
ttNc= Noncompliant

< 80% Noncompliant

80% Compliant

Total

I

19

I

14

I 33

I

10

I

14

I 24

28

57

29

Sensitivity = 19/29

* 100 = 66%

Specificity = 14/28

* 100 = 50%

Table 33:

Agreement between Gold Standard II(~ 90% compliance MEMS) and Self-report measure# 7
(Temptation to skip medication scale 13) for patients on Anti-retroviral.

MEMS
~

00
VJ

SELF-REPORT

Temptation to skip medication
Scale 13
I
13=tc
Temptation to skip medication
Scale 13
I
14+=ttNc

< 80% Noncompliant

80% Compliant

Total

15

I

10

I 25

13

I

18

I

31

'--

Total

28

28

Sensitivity = 15/28 * 100 = 54 %
Specificity = 18/28
t C= Compliant
ttNC= Noncompliant

* 100 = 64 %

56

'

Table 34:

Agreement between Gold Standard II (~ 90°/o compliance MEMS) and Self-report measure# 8
(Temptation to skip medication scale 13) for patients on Anti-retroviral.
MEMS
~

00
~

S1~LF-REPORT

Temptation to skip medication
Scale 13
13and 14=tc
Temptation to skip medication
Scale 13
15+=ttNc
Total

t C= Compliant
ttNC= Noncompliant

< 90% Noncompliant

Total

17

11

28

11

17

28

28

28

56

90% Compliant

Sensitivity = 17/28

* 100 = 61 %

Specificity= 17/28

* 100 = 61 %

(

REFERENCES

(

1.

Merriam, Websters New Collegiate Dictionary, Spring field MA, 1997.

2.

Altice FL et al., The era of adherence to HIV therapy, Annals of Internal
Medicine, 1998; 129:503-505.

3.

Sackett DL et al., The magnitude of compliance and noncompliance,
Compliance with therapeutic regimens, Baltimore: John Hopkins
University Press, 1976:11-27.

4.

Stewart KE et al., Pattern of self-reported adherence to ART in a
prospective clinical cohort, Interscience Conference for Antimicrobial
Agents Chemotherapy, 1998; 38: 420 (Abstract no. 1-176).

5.

Adherence to new HIV therapies: A research conference, National Institute
of Health office of AIDS Research, Washington DC 1997; 20-21.

6.

Melbourne KM et al., Medication adherence in patients with HIV
infection: A comparison of two measures, AIDS Reader, 1999; 9(5): 329338.

7.

Mostashari F et al., Acceptance and adherence with antiretroviral therapy
among HIV infected women in a correctional facility, Journal of Acquired
Immune Deficiency Syndrome Human Retroviral, 1998; 18(4): 341-348.

8.

Altice FL et al., Prescriptions, acceptance and adherence to antiretovirals
among prisoners, Fourth Conference on Retroviruses and Opportunistic
Infections, Washington DC, 1997; 22-26.

9.

Samet JH et al., Compliance with zidovudine therapy in patients infected
with human immunodeficiency virus, type 1: a cross-sectional study in a
municipal hospital clinic, American Journal of Medicine, 1992; 92(5):
495-502.

10.

Singh N et al., Determinants of compliance with Antiretroviral therapy in
patients with human immunodeficiency virus: prospective assessment with
implications for enhancing compliance, AIDS Care, 1996; 8(3): 261-269.

11.

Gordilla VR et al., Towards a new approach for the assessment of
to therapy, International Conference for AIDS, 1998; 12:598 (Abstract no.
32382).

85

(
12.

Bond SB et al., Detection methods and strategies for improving medication
compliance, American Journal of Hospital Pharmacy, 1991; 48:1978-1988.

13.

Dunbar J., Overview of adherence to medical treatment in program
summary of the adherence of new HIV treatments: A research conference,
Washington DC, the forum of collaborative HIV research (FCHR), The
National Minority AIDS Council (NMAC) and National Institute of Health
Office of AIDS research COAR), 1997; 20-21

14.

Cramer JA et al., Compliance declines between clinic visits, Archives of
Internal Medicine, 1990; 150(7): 1509-1510.

15.

Kass MA et al., Can ophthalmologist correctly identify patients defaulting
from pilocarpine therapy?, American Journal of Ophthalmology, 1986;
101(5): 524-530.

16.

Cramer JA et al., How often is medication taken as prescribed? A novel
assessment technique, Journal of American Medical Association,1989;
261(22): 3273-3277.

17.

Rudd Pet al., Resolving problems of measuring compliance with
medication Monitors, Journal of Compliance and Health Care, 1987; 2:2335.

18.

Gray LE et al., HIV treatment adherence: A guide for program
development, HIV/AIDS Project development and evaluation unit,
University of Washington School of Social work, Seattle, Washington,
1998; 1-60.

19.

Joseph JE., Antiretroviral resistance, Interscience Conference on
Antimicrobial Agents and Chemotherapy: Evolving HIV Treatments, 1998;
24-27.

20.

Chesney MA ., New anti retroviral therapies: Adherence challenges and
strategies, lnterscience Conference on Antimicrobial Agents and
Chemotherapy: Evolving HIV Treatments, 1997; Sep 28- Octl.

21.

Kass MA et al., Compliance with topical pilocarpine treatment, American
Journal of Ophthalmology, 1986; 101(5): 524-530.

22.

Kass MA et al., A miniature compliance monitor for eyedrop medication,
Archives of Ophthalmology, 1984; 102( 10): 15504-15554.

86

23 .

Kelsey JL et al., Measurement Error, Methods m Observational
Epidemiology, 1996; 26(2): 341-363.

24.

Kraemer HC., Ramification of a population model for k as a coefficient of
Reliability, Psychometrika, 1979; 44: 461 -472.

25.

Thompson WD et al. , A reappraisal of kappa coefficient, Journal of
Clinical Epidemiology, 1979; 41 :947-958.

26.

Morisky DE et al., Concurrent and predictive validity of a self-reported
measure of medication adherence, Medical Care, 1986; 24(1):67-74.

27.

Lilienfeld DE et al., Appendix: Selected statistical procedures, Foundation
of Epidemiology, 1994; 3: 287-332.

87

(

APPENDIX
•
•

Questionnaire
SAS Program
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Managing Your Medications Questionnaire
Pltast answtr tht following questions thoughifully and complutly. This qutstionnain is about
haw :you think andftd about the HIV relattld medications thal you ar1 taking, and about th• difftrenJ
strolegies that people use to tab their mtdicadons. When you tum it in, w• will give you a gift ctrtifical11
for$20tothankyoufor:yourparticipalian.
PATIENT I D : - - - - -

CODE FOR THIS Ql)ESTIONNAIRE:
A) What an the first 3 luters of your mothu's frm name 1

OOtCJOJCJO

B) Whet!: your birtl: date!

SECTION I
BACKG~pUND

INFORMATION

Thtfirst section of this questionnaire asks about your background.
::::>

Please drde or fill in the correct response for each question.

1. What is your age?

00ycars

2 . What is your gender?

M

F

3. How would you describe your current health status? (Please check one answer)

0

Excellent

0

Very Good

0

0

Good

Fair

0

Poor

4. Which of the following best describes your ethnic background?

0
0

White. non-Hispanic
Native American

0
0

0

Hispanic
Asian

0

African American
Other

DO

5. How many years of education have yoo finished?
(for example, for high school, fill in ·1r)
6. Do you currently work either part-time or full time'?

0

Full-time

0

Pan-time

0

I am not currently employed

Uniwn lry of 11:Jtod6 b'4nd. t:>l99d

89

7. Do you live by yourself or with other people?

0

0

Bymyself

With others

8. If you live with others, how many (besides you) arc in your household?

00

9. If you live with others, what is their relationship to you? (ChecJ: aU lha1 apply)

0
0
D
0

0
0

Husband or wife
Intimate partner
Other adults 18 or older
Parents

0

Grandparents
Children under age 18
Children over age iii

10. Do you have any children'? If so, how many? (If none, pul 0)

DD

11. Do any of your adult children live nearby (within a half hour drive)?

D

D

Yes

0

No

Not applicable

12. How many of your family or friends can you count on for emotional support?

13. How many of your family or friends can you count on for financial help?

DD

DD

14. How many of your family or friends can you count on for physical assistance,
or a place to stay? DO
15. Do you feel confident that your family or friends will continue to help you with your everyday needs?

D
0
D
D
D

Very confident
Fairly confident
Somewhat confident
Less than somewhat confident
Not at all confident

16. If you were to need more help with every day needs, do you feel confident that your family or friends
could provide it7

D

D
D
·O
D

Very confident
Fairly confident
Somewhat confident
Less than somewhat confident
Not at all confident

17. How many of your family & friends have you told about your HIV infection'?

0

None

D

Less than half

0

0

About half

90

More than half

D

All

18. What type of health insurance coverage do you currently have7

D
0
0
0
D

NONE

Rhode Island Elderly Assis~cc Program
Blue Cross
Ocean State
VA

0
0
0

Harvard Pilgrim Health Care (RIGHA, HCHP)
Other private insurer
0 Medicare
Other
0 Medicaid

19. Which of the following best estimates yoor total (family) income during the past 12 months?

D
D
D
D
0

....

Less than s15,ooo
s1s,ooo to $24,ooo
m.ooo to S34,ooo
S35,ooo to S44,ooo
$45,000 or more

20. About how far do you live from this treatment center?

0

Within walking distance
Within a ten minute drive or less
Within a twenty minute drive or· less
Within a thirty minute drive
More than thirty minutes away

0
0
0
0

21. When you have questions about medications for ycur HIV infection, who do you usually ask7
(P~ase check all that apply)
•

0
D
0

0

Pharmacist
Physician
Social Worker
Nurse

0
0
0
D

Other persons with HIV infection
Family members
Friends
Other; please specify_ _ _ _ _ _ _ _ _ _ __

22. Which health care provider is most helpful to you in taking your medications as directed?

0
0
0
0

D

Nurse
Pharmacist
Physician
Social Worker
Other, please specify_ _ _ _ _ _ _ _ _ _ __

23. Is there someone living with you or close to you who helps or reminds you to take your medications on
time7

D

Yes

D

No

91

24. How much bodily pain have you had during the past four

0
0

0

None
Very mild
Mild

D

0
0

w~lcs7

Moderate

Seven:
Very Severe

25. During the past 4 weeks, how much did HN-rclated symptoms interfere with your normal work
(including both work outside the home and housework}?

0

Not at all

0

A little bit

0

0

Moderately

0

Quite a bit

Extrcme.ly

00

26. During the past two weeks, how many days did you stay in bed all or most of the day'l
27. How many times have you been hospitalized in the past year'? (If none, put 0)

00

28. These questions are about how you feel and bow things have been with you during the past 4 weeks.
::::>

For each question, please give w one ~r rhal conus closest to the way you have been
feeling. How 11Uldi of w ~ dwing w past 4 wulc:r...
SOME

11rrornm

MOST
OFTIIE

A.LL

BlTOl'Tlll

or nm

A.GOOD

OFTHI:
T1.'dE

TINX

TIME

TIME

TIME

TIME

NONE

A.UT'rt.E

OFTIIE

a. Did you feel full of pep?

0

0

0

0

0

0

b. Have you been a very nervous
person?

0

0

0

0

0

0

c. Have you felt so down iii the dumps
that nothing could cheer you up?

0

0

0

0

0

0

d. Have you felt calm and peaceful?

0

0

0

0

0

0

e. Did you have a lot of energy?

0

0

0

0

f.

0
Have you felt downhearted and blue? 0

0

0

0

0

0
0

g. Did you feel worn out?

0

0

0

0

0

0

h. Have you been a happy person?

0

0

0

0

0

0

i. Did you feel tired'?

0

0

D

0

0

0

92

29. How long ago were you diagnosed as HlV positive?

0
0
0

Less than a month
One to six months
More than six months, but less than a year

0
0
0

l to2 years

3 to4years
S years or more

30. How do you think.you got your HIV infection?
Please chuk all that apply

0
0
0

0

0

Injection (IV) drug use
·Heterosexual contact
Homosexual contact
Blood transfusion
Other: - - - - - - - -

31. What was your T cell count (CD4 count) the last time you were tested7

0

Greater than 500

0

201-500

0

50-200

93

0

Less than 50

SECTION IIMEDICATION IIlSI'ORY
1.

WHICH OF THB FOLLOWING MEDICATIONS ARE PRESCRIBED FOR YOU NOW?
~
PLEASE CHECK ALL THAT APPLY:

0 Arr (R.etrovir®, zidovudine) 0
0
0 DOI (Videx®, didanosine)
0 DOC (Hivid®, zalcitabine) 0
0 D4T (Zerit®, stavudine)
0
0 3TC (Epivir®, lamivudine) 0
0
0 Nevirapine (Viramune®)
0
0 Delavirdine (R.escriptor®)
0 Saquinavir (lnvirase®)
0
0 Ritonavir (Norvir®)

Nelfinavir (Vira~pt®)
lndinavir (Crixivan®)
Trimethoprim· or SulfamethQ;tazol~ (Bactrim®, Septra®)
Clarithromycin (Biaxin®)
Dapsone
Fluconazole (Diflucan®)
ltraconazole (Sporanox®)
Rifabutin (Mycobutin®)

2 . How long have you been taking your protease inhibitor medication?

[Saquinavir (Invirme<!i>), RUonavir (Norrir@), NeQinavir (Vuucept) or IruUnavir (CrixiWJn<!i>)]
Less than 1 month
6 months to 1 year
- - 1 to 2 years
l to 3 months
~
'
-- - 4 to 6 months
_ _ more than 2 years
3. During the last 3 months, have you ever stopped taking your protease inhil>itor medication because you fdt
better?
DYES
ONO
4. During the last 3 months. have you ever stopped talcing your protease inhibitor medication because you fdt
worse?
·
DYES
ONO
5. During the last 3 months. have you ever forgotten to take your protease inhil>itor medication?
'

.

DYES

0

NO

6. During the last 3 months have you at times been careless about taking your protease inhibitor medication?
DYES
0 NO
7. During the last 3 months, have you ever taken less of your protease inhibitor medicine than your doctor
.prescribed because you fdt better?
DYES
D NO
8. During the last 3 months. have you ever taken less of your protease inlul>itor medicine than your doctor
prcscnl>cd because you fdt worse?
DYES
D NO

(
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9. Sinu you began ta.king your protease inhibitor medication, have you ever purposely:
'YES
NO
a) taken more of the medicine
than your physician prescribed?

0

0

b) taken less of the medicine
than your physician prescribed?

0

0

c) discontinued or stopped taking
your medication?

0

0

/[yes,
:::> 10.a) How many times have you discontinued your protease inhibitor medication for more

than 3 days?
b) What were your reasons for discontinuing your protease inhibitor medication?
Please check all that apply

0
0

0

0
0
0

My doctor ·recommended it
Too many side effects
I didn't want to be reminded of my illness
Problems with insurance coverage
.I didn't think it was working
Other:_·----------

11. Sometimes it is difficult to take prescribed medicine all the time. During the past week, how many
times did you miss a dose of your protease inhibitor?
12. During the past month, about how many times did you miss a dose of your protease
inhibitor'! _ _ __

13. During the past three mon~. aooJt how many times did you miss a dose of your protease
inhibitor?
---14. Please check any side effect(s) you are having that you believe are caused by your protease inhibitor
medicine:

0
0
0
0
0

l\all~
dizziness
vomiting
abdominal pain
diarrhea

0

other:

0
0
0
0

0

shortness of breath
muscle aches
fatigue
tingling in hands/feet
numbness in hands/feet
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0
0
0

0

0

headaches
anxiety/worry
depression

rash
sensitivity to sun

·1s.

How Jong have you been taking your antiviral medication? •
[AZT (Rctrol".r®, zUlovudint), DDI (Vida@, didanosint), DDC (Hivid@, raldlabint),
D4T ~ril®, stavudint), 3TC (Epivir®, lamivudinc), or Nnirapint (V'uomunt)}
_ _ .l.o3-lhan 1 month
_ _ 6 months to l year
1 to 3 months
_ _ 1 to 2 years
4 to 6 months
_ _ more than 2 years

16. During the last 3 months have you ever stopped taking your antiviral medication because you fdt better?
0 YES
0 NO
17. During the last 3 months, have you ever stopped taking your antiviral medication because you felt worse?
0 YES
D NO
18. During the last 3 months, have you ever forgotten to take your antiviral medication?
DYES
D NO

19. During the last 3 montlu have you at times been careless about taking your antiviral medication?
0 YES
0 NO
20. During the last 3 months, have you ever taken Jess of your antiviral medicine than your doctor prcscnl>ed
because you (dt better?
0 YES
D NO

21. During the last J months, have you ever taken less of your antiviral medicine than your doctor prescnl>ed
because you fdt worse?
DYES
0 NO

22. Since you btgan taking your antiviral medication, have you ever purposely:

YES

NO

a) taken more of the medicine
than your physician prescribed?

0

0

b) taken less of the medicine
than your physician prescribed?

0

0

c) discontinued or stopped talcing
your medication?

0

0

If yes,
=:>

23.a) How many times have you discontinued your antiviral medication for more than 3
days?

96

b) What were your reasons for discontinuing your antiviral medic:ition?
Please check all thar apply

0
0
0
0
0
0

My doCtor recommended it
Too many side effects
I didn't want to be reminded of my illness
Problems with insurance coverage
I didn't think it was working
Other:------------

24. Sometimes it is difficult to take prescribed medicine all the time. During the past week, how mnny
times did you miss a dose of your antiviral medication?
25. During the past month, about how many times did you miss a dose of your antiviral
medication? _ _ __
· 26. During the past three months, about how many times did you miss a dose of your antiviral
. medication?
·
TT. Please check any side effecl(s) you arc having that you believe are caused by your antiviral medicine:

0
D
0

nausea

0
0

dizziness
vomiting
abdominal pain
diarrhea

0

other:

0
0
0
0

0

shortness of breath
muscle aches
.fatigue
tingling in hands/feet
numbness in hands/feet
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0
0
0
0

0

headaches
anxiety/worry
depression
rash
sensitivity to sun

SECTION III
ANTIVIRAL MEDICATIONS
REMINDER: FILL our THIS SECTION IF YOU HA VB BYER TAKEN ANY OF THESE ANTIVIRAL
MEDICATIONS: AZT (Relrovir®, zidovudine), DDl (Videx®, didanorlne), DDC (Hivid®, z:alcitabin1),
D4T (Zerit@, stavudlne), 3TC (Epivir®, lamivudine). Neviropine (Vuumune®), or IHlavirdine
(Rescriptor®).
::::> 1f you

are taking more tf?!!ll O"!:e c.n.tiviral medication NOW, pltase answer these questions
for the medicine that is most di[fiat.l:t for JOU to take, and fill in the name of that
medicine hen
~~~~~~~~~~~~~~~~~~-

::::> 1f you "JuJve

discontinued your antiviral medication, pkase answer thest1 questions
for the medicine that you took most ncaitly, and fill in the name of that
medicine hen
~~~~~~~~~~~~~~~~~~-

Taking medications a.S directed (the prescribed amount taken at the right time) is not always c:osy. At
one time or another most people simply for~ to take a dose of their medication, and sometimes people
discontinue taking their medications for a while. lbe following is a list of Possible advantages and
disadvantages of taking antiviral medications as dicectcd.
::::>

For each rwmberlll stawnent, please mark one box with an ·x· to rate HOW IMPORTANT that
statement is to you when you are thinking about whnher to take your antiviral medicalion as
directed.
NOT
IM!'OltTAh"T

SLIGBTI.Y
IMlORTAh"T

MODERAn:LY
IMl'ORTANT

VEXY
IMl'ORTANT

EXTREMELY
IM?QRTANT

0

0

0

D

0

2. When I take my antiviral medication
as directed, it makes me feel depressed
about having RN infection.

0

D

D

D

D

3. Taking my antiviral medication as directed

0

D

0

D

D

4. Taking my antiviral medication as directed
will slow down this illness.

0

0

0

D

0

5. I worry that taking all the doses that are
prescribed might not be good for me.

0

D

0

D

0

l. If I take my antiviral medication

as directed, I can avoid possible
complications of HIV infection.

causes too many annoying side effects.
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(
NOT
IMJ'OKTANT

SUGHTLY
IMJ'QRTANT

MODERATELY
llll?ORTANT

VERY
lllll'ORTANT

EXTllD>IELy
IM?'ORTANT

6. Taking my antiviral medication as directed
gives me hope.

D

0

0

0

0

7. I worry that the antiviral medication

D

0

0

0

0

8. Taking my antiviral medication as directed
may help me stay well longer.

D

0

CT

0

0

9. It may be hard on my system, if I take
my antiviral medication as directed.

D

0

D

0

D

10. Taking my antiviral medication as directed
will help me feel better.

0

D

D

0

0

.

is-doing more harm than good .

Sometimes people take their medications as di_rccted for a while, and then stop taking them for a while.

=>

~following

2

qu~tions

are about how you are taking your antiYiral mediauion RIGHT NOW.

11. Do you consistently take your antiviral medication as dirccted7 (Mas directedft means taking your
medication at the right time and taking the prescribed amount)
a. Ne., I <io uot, ~d I am not considering taking my antiviral medication as
directed.
b. No, I do not, but I am considuing taking my antiviral medication as directed.
c. No, I do not, but I am planning to start taking my antiviral medication as directed
within the next month.
d. Yes, I consistently take my antiviral medication as directed.

=

12. How long have you been taking your antiviral medication as
directed?

a.
b.
c.
d.

0-3 months
4-6 months
6-12 months
more than 12 months
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(
Now here arr: some situations that might affect whether you take your antiviral medication for HIV
infection as directed.
=:>

For each situation. please mark one box with an ·x· to raJt HOW TEMPTED you would bt to
skip your antiviral mMication or tukt a dost which ls difftrtnt from tht one prtScribtd.
NOT AT

SUClrTl.Y

ALL TEMJ'TC) TDO'TED

MODERAn:LY
TEMl'TED

VERY

EXTllEMELY

TEMrnD

TEMrnD

·o

D

Lf

0

0

14. When you are anxious about side
effects.

D

0

0

0

0

l~.

0

0

0

0

D

16. When your medical condition doesn't
seem that bad.

D

0

0

0

0

17. When it seems too complex to keep track
of all your medications.

0

0

D

0

0

18. When you feel like giving up.

0

0

0

0

0

19. When you aren't sure if the medicine is
really helping you.

0

0

D

0

0

20. When your family or friends don't seem
concerned enough about your condition.

0

0

0

0

0

21. When your doctor doesn't seem concerned
enough about your condition.

0

0

0

0

0

22.. When your insurance doesn't cover

0

0

D

D

D

23. When you lose confidence in your doctor.

0

0

0

D

0

24. When you feel you should give your body
a rest.

0

0

0

0

0

25. When you worry that the chemicals in the
medication might harm or hurt your
body.

0

0

0

0

0

13. When you feel good and think you don't
need it.

When you experience minor side effects.

the cost of your medication.
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SECTION IV.
PROTEASE INHIBITOR MEDICATIONS
REMINDER: FILL our THIS SECTION IF YOU HA VB BVBR TAKEN ANY OF THESE PROTEA.SB
INHmITOR MEDICATIONS: Saquirurrir (lnvira.st®), Ritonavir (Norvir®), Ntlfuiavir (Virocept@) or
Indina11ir (Crixi11an@).

=> If you an taking more than ont protease inlUbitor medication NOW, please answer these
questions for tht nwiidne that is most dUficult for you (o taki;, and fill in tht r.i:me of
thal medicine htrc
••
=> If you hCll'e disconmwed your protease inhWitor medication, please answer these questions for
the medicine that you took m'1St recently, and fill in the namt of thal medicine here

Taking medications as directed (the prescribed amount taken at the right time) is not always easy. At
one time or another most people simply forget to take a dose of their medication, and sometimes people
discontinue taking their medications for a while. 1'be following is a list of possible advantages and
disadvantages of taking protease inhibitor medications as directed.

=> For each numbered statement, p~ maric one box with an ·x· to rote HOW IMPORTANT that
.staJcnent i.s to )'OM when you are thinking about whtthtr to take your protease inhibitor
medication as dincted.
NOT
D\a'OltTANT

SUCBTLY
IM!'OKT ANT

MODERATELY
IMPORTANT

VERY
IMl'ORTANT

EXTREMELY
IMl'ORTANT

1. If I take my protease inhibitor medication
as directed, I can avoid possible
complications of HIV infection.

D

D

D

D

D

2. When I take my protease inhibitor
medication as directed. it makes me feel
depressed about having HIV infection.

D

D

0

0

0

3. Taking my protease inhibitor medication
as directed causes too many annoying
side effects.

D

D

D

0

0

4. Taking my protease inhibitor medication
as directed will slow down this illness.

D

0

D

D

D

5. I worry that taking all the doses that are

D

D

D

0

D

D

0

D

0

0

prescribed might not be good for me.

6. Taking my protease inhibitor medication
as directed gives me hope.

::.~~
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NOT
IMroRTANT

SUCllTLY.
l!llroRTANT

0

0

D

D

·o

0

0

0

D

0

9. It may be hard on my system, if I take my D
protease inhibitor medication as directed.

0

o·

D

0

0

0

D

D

0

'·

I worry that the protease inhibitor
medication is doing more harm
than good.

8. Talcing my protease inhibitor medication

as directed may help me stay well longer.

10. Talcing my protease inhibitor medication
as directed will help me feel better.

MOD£RAT£LY
IM?'ORT AN!'

V'DtY
IMroRTANJ'

EXTltEMELY
IMroRTANT

Soiµetimes people take their medications as directed for a while, and then stop taking them for a while.
~

The follcwing 2 qru.stions all about how you all taking your prouase inhibitor medication
RIGHT NOW.

11. Do you consistently take your protease inhibitor medication as dircctcd7 c·as
your medication at the right time and talcing the prescribed amount)

directed~

means talcing

_ _ a. No, I do not, and I am not considering talcing my protease inhibitor medication as
directed.
b. No, I do not, but I am considering taking my protease inhibitor medication as
directed.
c. No, I do not, but I am planning to start talcing my protease inhibitor medication as
directed within the next month.
d. Yes, I consistently ta1ce my protease inhibitor medication as directed.

=;>

12. How long have you been taking your protease inhibitor medication as
directed7

a.
b.
c.
d.

0-3 months
4-6 months
&-12 months
more than 12 months
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Now here arc some situations that might affcc:t whether you Ukc your protease inhibitor medication
for HIV infection as directed.
:::::>

For tach situation, pltast mark ont bo:c with an -x· to rott HOW TEMPTED you would bt to
skip your prottast inhibitor mtdication or take a dose which ls difftlllllfrom the one
prtscribtd.
NOT AT

SUGBTLY

AU~ TEMJ"n;J>

MODDlATELY
Tu.lrn:D

VERY
TEMrrED

EXI'IU:MELY
TEMPTED

~.

13. When you feel good and think you don't
need it.

D

D

D

·D

0

14. When you arc anxious about side effects.

D

D

0

D

0

15. When you experience minor side effects.

D

D

0

0

D

16. When your medical condition doesn't
seem that bad.

D

D

0

D

D

D

D

0

0

D

18. When you feel like giving up .

D

D

0

D

D

19. When you aren't sure if the mcdici.Qe is

D

D

0

0

D

20. When your family or friends don't seem
concerned enough about your condition.

D

D

0

0

0

21. When your doctor doesn't seem
concerned enough about your condition.

D

D

0

D

D

22. When your insurance doesn't cover
the cost of your medication.

0

0

0

0

0

23. When you lose confidence in your doctor.

D

D

0

0

D

24. When you feel you should give your body
a rest.

0

D

D

0

0

25. When you worry that the chemicals in the
medication might hann or hurt your
body.

D

D

0

0

D

17. When it seems too complex to keep
of all your medications.

;

tra<:~

really helping you.
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For information on !he MMcdication for The Needy-Assistance Program• at The Univcrsiry or Rhode Island,
call 1-800-215-9001.
This completes this survey. Thank you for your assistance with th1s project & for sharing your
thoughts on HIV related medications.
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libname research 'd:\research';
data research.new;
set research.hivshrt;
*new variable for age called agegrp coded as 1,2,3 and 4;
if 20 le qi1 le 25 then agegrp=1;
else if 26 le qi1 le 35then agegrp=2;
else if 36 le qi1 le 45 then agegrp=3;
else if 46 le qi1 le 55 then agegrp=4;
*new variable for education called edu coded as 1 2 3 and 4;
if qi5<12 then edu=1;
else if qi5=12 then edu=2;
else if 13 le qi5 le 15 then edu=3;
else if qi5 ge 15 then edu=4;
*new variable for employment called emp coded as 1 2
if qi6=1 or qi6=2 then emp=2;
else if qi6=3 then emp=1;
*recoding for drugnam1

drunam2 and drugnam3 1=pi 2=ar and 3=ai;

if drugnam1='saqinavir' or drugnam1='invirase' or drugnam1='ritonavir
or drugnam1='norvir' or drugnam1='crixivan' or drugnam1='nelfinavir'
then drugnam1=1;
else if drugnam1=' ' then drugnam1=' .';
else if drugnam1= 'AZT' or drugnam1= 'retrovir' or drugnam1= 'zidovud
or drugnam1='videx' or drugnam1= 'didanosine'or drugnam1='DDC' or dru
drugnam1= 'zalcitabine' or drugnam1= 'D4T' or drugnam1= 'zerit' or dr
drugnam1= '3TC' or drugnam1='epivir' or drugnam1='lamivudine' or drug
or drugnam1='viramune' or drugnam1='delavirdine' or drugnam1= 'rescri
else drugnam1=3;
if drugnam2='saqinavir' or drugnam2='invirase' or drugnam2='ritonavir
or drugnam2='norvir' or drugnam2='crixivan' or drugnam2='nelfinavir'
then drugnam2=1;
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else if drugnam2=' ' then drugnam2=' .';
else if drugnam2= 'AZT' or drugnam2= 'retrovir' or drugnam2= 'zidovud
or drugnam2='videx' or drugnam2= 'didanosine'or drugnam2='DDC' or dru
drugnam2= 'zalcitabine' or drugnam2= 'D4T' or drugnam2= 'zerit' or dr
drugnam2= '3TC' or drugnam2='epivir' or drugnam2='lamivudine' or drug
or drugnam2='viramune' or drugnam2='delavirdine' or drugnam2= 'rescri
else drugnam2=3;
if drugna~3='saqinavir' or drugnam3='invirase' or drugnam3='ritonavir
or drugnam3='norvir' or drugnam3='crixivan' or drugnam3='nelfinavir'
then drugnam3=1;
else if drugnam3=' ' then drugnam3='. ';
else if drugnam3= 'AZT' or drugnam3= 'retrovir' or drugnam3= 'zidovud
or drugnam3='videx' or drugnam3= 'didanosine'or drugnam3='DDC' or dru
drugnam3= 'zalcitabine' or drugnam3= 'D4T' or drugnam3= •zerit' or dr
drugnam3= '3TC' or drugnam3='epivir' or drugnam3='lamivudine' or drug
or drugnam3='viramune' or drugnam3='delavirdine' or drugnam3= 'rescri
else drugnam3=3;
*recoding the variables included in the mas scale as O and 1;
if qiiav16=1 then qiiav16=0;
else if qiiav16=2 then qiiav16=1;
else qiiav16='. •;
if qiiav17=1 then qiiav17=0;
else if qiiav17=2 then qiiav17=1;
else qiiav17='. •;
if qiiav18=1 ~hen qiiav1B=O;
else if qiiav18=2 then qiiav18=1;
else qiiav18='. •;
if qiiav19=1 then qiiav19=0;
else if qiiav19=2 then qiiav19=1;
else qiiav19='. •;
if qiiav20=1 then qiiav20=0;
else if qiiav20=2 then qiiav20=1;
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(

else qiiav20='. ';
if qiiav21=1 then qiiav21=0;
else if qiiav21=2 then qiiav21=1;
else qiiav21='.';
if qiipi3=1 then qiipi3=0;
else if qiipi3=2 then qiipi3=1;
else qiipi3='.';
if _qiipi4=1 then qiipi4=0;
else if qiipi4=2 then qiipi4=1;
else qiipi4='.';
if qiipi5=1 then qiipi5=0;
else if qiipi5=2 then qiipi5=1;
else qiipi5='. •;
if qiipi6=1 then qiipi6=0;
else if qiipi6=2 then qiipi6=1;
else qiipi6='.';
if qiipi7=1 then qiipi7=0;
else if qiipi7=2 then qiipi7=1;
else qiipi7='. ';
if qiipi8=1 then qiipiS=O;
else if qiipi8=2 then qiipi8=1;
else qiipi8='.';
MAS AV= qiiav16+qiiav17+qiiav18+qiiav19+qiiav20+qiiav21;
MAS PI= qiipi3+qiipi4+qiipi5+qiipi6+qiipi7+qiipi8;
TEMP13AV= qiii23+qiii24+qiii28+qiii34+qiii36+qiii37+qiii40+
qiii44+qiii47+qiii48+qiii49+qiii51+qiii52;
TEMP12AV= qiii23+qiii24+qiii28+qiii34+qiii36+qiii40+
qiii44+qiii47+qiii48+qiii49+qiii51+qiii52;
TEMP13PI=qv23+qv24+qv28+qv34+qv36+qv37+qv40+qv44+qv47+qv48+qv49+qv51+
TEMP12PI= qv23+qv24+qv28+qv34+qv36+qv40+qv44+qv47+qv48+qv49+qv51+qv52
*avm1 avm2 avm3 are three sub categories for mas av and pim1 pim2 pim
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if mas_av=O then avm1=0;
else if 1 le mas av le 6 then avm1=1;
else avm1='. •;
if mas av=O or mas_av=1 then avm2=0;
else if 2 le mas av le 6 then avm2=1;
else avm2=' . • ;
if mas_av=O or mas_av=1 or mas av=2 ~hen avm3=0;
else if 3 le mas av le 6 then avm3=1;
else avm3= • . • ;
if mas_pi=O then pim1=0;
else if 1 le mas_pi le 6 then pim1=1;
else pim1='. ';
if mas_pi=O or mas_pi=1 then pim2=0;
else if 2 le mas_pi le 6 then pim2=1;
else pim2= • . • ;
if mas_pi=O or mas_pi=1 or mas_pi=2 then pim3=0;
else if 3 le mas_pi le 6 then pim3=1;
else pim3='.';
if temp12av=12 then av12t1=0;
else if 13 le temp12av le 38 then av12t1=1;
else av12t1='.';
if temp12av=12 or temp12av=13 then av12t2=0;
else if 14 le temp12av le 38 then av12t2=1;
else av12t2='. •;
if temp12av=12 or temp12av=13 or temp12av=14 then av12t3=0;
else if 15 le temp12av le 38 then av12t3=1;
else av12t3=' .';

if temp12av=12 or temp12av=13 or temp12av=14 or temp12av=15 then av12
else if 16 le temp12av le 38 then av12t4=1;
else av12t4=' .';
if temp13av=13 then av13t1=0;
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else if 14 le temp13av le 42 then av13t1=1;
else av13t1='.';
if temp13av=13 or temp13av=14 then av13t2=0;
else if 15 le temp13av le 42 then av13t2=1;
else av13t2= '.';
if temp13av=13 or temp13av=14 or temp13av=15 then av13t3=0;
else if 16 le temp13av le 42 then av13t3=1;
else av13t3=' . ' ;
if temp13av=13 or temp13av=14 or temp13av=15 or temp13av=16 then av13
else if 17 le temp13av le 42 then av13t4=1;
else av13t4=' . ' ;
if temp12pi=12 then pi12t1=0;
else if 13 le temp12pi le 60 then pi12t1=1;
else pi12t1='. • ;
if temp13pi=13 then pi13t1=0;
else if 14 le temp13pi le 65 then pi13t1=1;
else pi13t1=' . ' ;
if 80 le dosepct1 le 100 then mems1=0;
else if dosepct1=. then mems1=.;
else mems1=1;
if 90 le dosepct1 le 100 then mems2=0;
else if dosepct1=. then mems2=.;
else mems2=1;
* new variable for # doses missed;
OM= {90-qiipi12}/90*100;
TM= {270-qiipi13}/270*100;
if 80 le om le 100 then om1=0;
else if om=. then om1=.;
else om1=1;
if 90 le om le 100 then om2=0;
else if om=. then om2=.;
else om2=1;
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if 80 le tm le 100 then tm1=0;
else if tm=. then tm1=.;
else tm1=1;
if 90 le tm le 100 then tm2=0;
else if tm=. then tm2=.;
else tm2=1;

run;
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